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BIOLOGICAL AND CLINICAL MARKERS OF NEURONAL INJURY IN PRIMARY
AND CHRONIC HIV-1 INFECTION. Michael J. Peluso, Dieter Meyerhoff, Julia
Peterson, Evelyn Lee, Andrew Young, Francesca Ferretti, Antonio Boschini, Rudy
Walter, Nancy Angoff, Kevin Robertson, Dietmar Fuchs, Bruce Brew, Paola Cinque,
Lars Hagberg, Henrik Zetterberg, Magnus Gisslén, Richard Price, and Serena Spudich,
Department of Neurology, Yale University School of Medicine, New Haven, CT.
The use of antiretroviral therapy (ART) has shifted the neurological manifestations of
HIV-1 infection toward mild but debilitating HIV-associated neurocognitive disorder
(HAND). Through two studies, we sought to characterize neuronal injury during primary
and chronic HIV infection and to describe its relationship with HAND.
The aim of the first study was to quantify cerebrospinal fluid (CSF) and
neuroimaging biomarkers of neuronal injury in primary HIV infection (PHI). We
compared CSF levels of neurofilament light chain (NFL), tau, and amyloid proteins in 92
subjects with PHI and 25 controls and examined relationships with disease progression
and neuroinflammation, neuropsychological testing, and proton-magnetic resonance
spectroscopy (MRS). We hypothesized that PHI is characterized by increased CSF NFL
that correlates with neuronal inflammation, and that tau and amyloid levels are normal in
PHI. NFL was elevated in PHI (p=0.0004) and correlated with CSF neopterin (r=0.38,
p=0.0005), IP-10 (r=0.39, p=0.002), WBCs (r=0.32, p=0.004), and CSF:plasma albumin
ratio (r=0.60, p<0.0001). NFL correlated with decreased N-acteylaspartate and glutamate
in the anterior cingulate, frontal white matter, and parietal gray matter (r>0.30, p<0.05).
Beta-amyloid was elevated in PHI (p=0.0005) and correlated with time infected (r=0.34,
p=0.003). Neither marker correlated with neuropsychological abnormalities. T-tau and
amyloid precursor proteins did not differ between groups.
The aim of the second study was to characterize HIV-infected patients with
neuro-symptomatic CSF ‘escape,’ defined as detectable CSF HIV RNA in the setting of

2

treatment-suppressed plasma levels or CSF RNA >1 log higher than plasma RNA. We
conducted a retrospective case series of virologically controlled HIV-infected patients on
ART with progressive neurological abnormalities who were determined to have CSF
‘escape’ at 4 urban medical centers in the United States and Europe. We recorded levels
of CSF HIV RNA and inflammatory markers, clinical signs and symptoms, and magnetic
resonance imaging (MRI) findings. We hypothesized that individuals with this condition
would have inflammation in CSF and MRI studies, that CSF virus would be resistant to
the ART regimen, and that symptoms would improve when ART was changed based
upon central nervous system (CNS) drug penetration and resistance genotyping. 10
patients presented with sensory, motor, and cognitive abnormalities. Median CSF HIV
RNA was 3900 copies/mL; median plasma HIV RNA was 62 copies/mL. Median CD4+
T cell count was 482 cells/mm3. All patients had been controlled <500 copies/mL for
median 27.5 months and 5/10 had been suppressed <50 copies/mL for median 19.5
months. Patients were on a stable ART regimen for median 21 months. All had CSF
pleocytosis or elevated CSF protein; 7/8 had MRI abnormalities; and 6/7 harbored CSF
resistance mutations. Following optimization of ART, 8/9 patients improved clinically.
Although these processes occur at distinct time points in the disease, both
neuronal injury during PHI and the development of symptomatic CSF ‘escape’ in
chronic, well-treated infection are associated with, and possibly caused by, mechanisms
involving immune activation and inflammation within the CNS. The inflammatory milieu
induced by the activity of HIV in invading cells and triggering an immune response has
important implications throughout the time course of infection, and may be particularly
important for understanding the pathophysiology of HAND.
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INTRODUCTION
Thirty Years Later: HIV Beyond the Immune System
Thirty years after the report of five unexplained cases in Los Angeles of Pneumocystis
carinii pneumonia in men suffering from what would become recognized as the acquired
immunodeficiency syndrome (AIDS) [1], the human immunodeficiency virus (HIV)
remains the subject of intense biochemical, molecular, clinical, and epidemiologic
investigation. HIV is a blood-borne and sexually transmitted infection that has significant
implications for both individual and public health and has disproportionately affected
vulnerable and marginalized individuals and populations, including the poor and
underserved, injection drug users, commercial sex workers, and men who have sex with
men [2]. But the epidemic has also changed: HIV has no regard for gender, age, or
sexuality and what once was largely a disease of young homosexual men has expanded to
affect populations that are older, heterosexual, and female.
It is estimated that there are currently 34 million people living with HIV
worldwide, that there are 2.5 million new infections annually, and that 1.7 million
individuals die from the disease and its sequelae each year [2,3]. And while the greatest
number of new infections and the worst outcomes occur in the lowest-resource settings in
sub-Saharan Africa and southeast Asia, there are still nearly 50,000 individuals who are
newly infected within the United States each year [2]. Despite the progress that has been
made over the last three decades, the epidemic is far from over (Figure 1a-d).
While a better understanding of the virus’ characteristics, including its
pathogenesis and transmission patterns, has led to both prophylactic and therapeutic
interventions, many questions about the disease’s pathogenesis remain unanswered. In
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a.

b.

c.

d.

Figure 1. The epidemiology of HIV infection in 2011. a. Estimated HIV prevalence by country, demonstrating significant prevalence worldwide
and high prevalence in sub-Sarahan Africa and Asia. b. Total number of adults living with HIV; size of circles corresponds with absolute number of
individuals. c. HIV prevalence among injection drug users, note the especially high prevalence in Asian countries. d. Total number of women living
with HIV infection worldwide; this has increased significantly over the last 20 years. Adapted from AIDSinfo at unaids.org [3].
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particular, the last two decades have seen an increased focus on the effects of HIV
beyond the immune system, including its end-organ effects in the cardiovascular, renal,
and nervous systems. By extension, the study of the virus in these new contexts outside
of the plasma has led to the recognition of a biological compartmentalization that allows
for infection and injury of target tissue, independent evolution of the virus from its
counterparts in the plasma, and the protection of the virus from systemic therapy [4,5].
The development of these distinct biological compartments, such as those in the breast
[6,7] and genital tract [8,9], facilitates viral replication, complicates viral eradication, and
leads to compartment-specific effects. One compartment that has received increased
attention over the last decade is the central nervous system (CNS) [4,10-12].
HIV infection is associated with the establishment of a CNS reservoir of
infection, as evidenced by the detection of HIV DNA in perivascular brain macrophages,
microglial cells, and astrocytes [13-15], compartmentalization of HIV quasi-species in
CNS tissues [16,17], and clinical cases of isolated CNS ‘escape’ from antiretroviral
therapy (ART) [18,19]. This local infection leads to neurological injury and creates a
sanctuary for ongoing HIV replication within CNS tissues. Understanding the initial
establishment and clinical importance of this CNS compartment-specific infection has
critical implications for strategies to optimize the lives of persons infected with HIV.

“Classic” Neurological Manifestations of HIV Infection
The neurological manifestations of HIV were first described in the early stages of the
epidemic and were quickly recognized as some of the most dramatic sequelae of HIV
infection. The AIDS Dementia Complex – an early-onset, progressive dementia
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characterized by motor, psychological, and behavioral dysfunction – was the most
dreaded of these complications and became the grim reality for many HIV-infected
individuals once they developed AIDS [20,21]. Patients with AIDS were also at risk for
developing CNS opportunistic infections with organisms like Toxoplasma gondii,
Cryptococcus neoformans, and Mycobacterium tuberculosis, CNS lymphoma linked to
Epstein-Barr virus, JC virus-associated progressive multifocal leukoencephalopathy, and
meningitis related to bacterial, viral, and fungal pathogens. These neurological
manifestations of the disease were dramatic and the prognosis in patients with such
manifestations was grim.
Clinical manifestations of the AIDS Dementia Complex in the absence of
antiretroviral therapy were mirrored in clear CNS abnormalities on pathological
evaluation, including profound infiltration of immune cells into the CNS, with
subsequent inflammation and HIV virions detected most abundantly in macrophages and
microglial cells of the deep gray matter of the brain [21-23]. In chronic, established
infection, even in patients without dementia, HIV DNA has been recovered from
homogenized brain tissue and specific cell types in the CNS including macrophages,
microglia, and astrocytes [17,22,24,25]. Neurons themselves, while not productively
infected by HIV, appear to be damaged and undergo apoptosis through “indirect”
pathways mediated by immune activation and inflammation within the CNS [26,27].
The introduction of combination antiretroviral therapy (cART) in the 1990s
fundamentally altered the landscape of both systemic and neurological HIV disease. The
profound immunodeficiency associated with HIV/AIDS that acted as the substrate for the
“classic” neurological manifestations of the disease itself and the opportunistic infections
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with which it was associated could now be significantly delayed or prevented,
transforming the diagnosis of HIV infection from a rapid death sentence to a chronic
illness. With these changes came a marked shift in the epidemiological and clinical
characteristics of its neurological complications.

Neurological Manifestations of HIV in the Era of Antiretroviral Therapy
In general, antiretroviral therapy suppresses both plasma and cerebrospinal fluid (CSF)
viral levels and improves neurological outcomes in patients infected with HIV [28].
Typically, plasma HIV RNA suppression is paralleled by suppression in the CSF, and the
initiation of cART also limits the extent of immune activation in the CSF, as measured by
white blood cell counts and immunological markers [29,30]. With systemic control of the
virus and improved immune status in these patients has come a striking decline in the
occurrence of neurological opportunistic infections, while the attenuation of viral
replication and immune activation in the CNS has resulted in a decline in the incidence of
the most dramatic forms of HIV-associated neurologic disease over the last two decades
[31]. Nevertheless, even individuals with well-controlled HIV infection continue to
experience neurological dysfunction which, although often less pronounced than the
dementing illnesses experienced by many patients with AIDS thirty years ago, has the
potential to seriously impact productivity and quality of life [32-35].

HIV-Associated Neurocognitive Disorder (HAND)
With improved outcomes and the recognition of a broad spectrum of neurological signs
and symptoms associated with HIV have come a variety of classification systems for

10

clinicians and researchers to describe the manifestations of CNS disease experienced by
patients with HIV and AIDS. What was previously defined in its most severe form as the
AIDS-Dementia Complex [20,21] is now represented by a spectrum of disorders
reflecting the variability in presentation, outcome, and impact of neurological disease.
HIV-associated neurocognitive disorder (HAND) comprises a diverse set of
neurocognitive diseases, ranging from clinically asymptomatic impairment to severe
dementia. HAND is a clinical diagnosis defined by abnormalities identified through
neuropsychological testing and is subdivided into three categories of increasing severity:
asymptomatic neurocognitive impairment (ANI), mild neurocognitive disorder (MND),
and HIV-associated dementia (HAD) [36]. These diagnoses require a specific
neuropsychological testing battery comprised of the following abilities: verbal/language,
attention/working memory, abstraction/executive functioning, memory (learning and
recall), speed of information processing, sensory-perceptual, and motor skills. While the
incidence of the most severe manifestations of HAND (i.e., HAD) has decreased in the
setting of widespread access to cART, mild-to-moderate HAND has persisted and has, in
fact, become the most prevalent primary CNS complication of HIV infection [33]. The
spectrum of HAND is delineated in the Table 1 and key differences between conditions
are explained in the subsequent text.

Asymptomatic Neurocognitive Impairment (ANI)
The most benign and most common manifestation of HAND is asymptomatic
neurocognitive impairment, which has been identified in approximately one-third of
HIV-infected patients [33]. Decreased performance on neuropsychological testing in
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Asymptomatic Neurocognitive Impairment (ANI)
1. Acquired impairment in cognitive functioning, involving at least two ability domains,
documented by performance of at least 1.0 SD below the mean for age- and educationappropriate norms on standardized neuropsychological tests.
2. The cognitive impairment does not interfere with everyday functioning.
3. The cognitive impairment does not meet criteria for delirium or dementia.
4. There is no evidence of another preexisting cause for the ANI.
Mild Neurocognitive Disorder (MND)
1. Acquired impairment in cognitive functioning, involving at least two ability domains,
documented by performance of at least 1.0 SD below the mean for age- and educationappropriate norms on standardized neuropsychological tests.
2. The cognitive impairment produces at least mild interference in daily functioning, as
evidenced by at least one of the following:
a) Self-report of reduced mental acuity, inefficiency in work, homemaking, or social
functioning.
b) Observation by knowledgeable others that the individual has undergone at least mild
decline in mental acuity with resultant inefficiency in work, homemaking, or social functioning.
3. The cognitive impairment does not meet criteria for delirium or dementia.
4. There is no evidence of another preexisting cause for the MND.
HIV-Associated Dementia (HAD)
1. Marked acquired impairment in cognitive functioning, involving at least two ability domains;
typically the impairment is in multiple domains, especially in learning of new information, slowed
information processing, and defective attention/concentration. The cognitive impairment must
be ascertained by neuropsychological testing with performance of at least 2.0 SD less than
than demographically corrected means.
2. The cognitive impairment produces marked interference with day-to-day functioning such as
work, home life, or social activities.
3. The pattern of cognitive impairment does not meet criteria for delirium (i.e., clouding of
consciousness is not a prominent feature); or, if delirium is present, criteria for dementia need
to have been met on a prior examination when delirium was not present.
4. There is no evidence of another, preexisting cause for the dementia (i.e., other CNS
infection, CNS neoplasm, cerebrovascular disease, preexisting neurologic disease, or severe
substance abuse compatible with CNS disorder).
Table 1. Classification and description of HIV-associated neurocognitive disorder (HAND)
in the era of combination antiretroviral therapy. Key distinctions between the three disorders
are described in the text. Adapted from Antinori et al., 2007 [36].
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patients without obvious clinical signs and symptoms of impairment has led to the
classification of ANI, which is characterized as a subclinical cognitive decline. The strict
definition of ANI requires the presence of mild neuropsychological impairment, not
attributable to comorbid conditions, involving 2 or more ability domains on
neuropsychological testing. ANI specifically requires that criteria for a negative impact
on everyday functioning not be met; this is how the condition is contrasted from mild
neurocognitive disorder.
It is unclear whether ANI is a process predictive of neurological impairment later
in the course of the disease, whether it contributes to neuropathological vulnerability, and
whether early intervention with cART during ANI might prevent ongoing deterioration
[37]. Additionally, the ANI designation is not specific for active brain injury, and may be
complicated by confounding factors related to HIV disease, such as mood disorders or
substance abuse. The contribution of such comorbidities might be difficult to ascertain in
patients with ANI.

Mild Neurocognitive Disorder (MND)
Mild neurocognitive impairment is being increasingly recognized in individuals treated
with cART, who typically have a relatively reconstituted immune system characterized
by higher CD4+ T cell counts and suppressed or undetectable viral loads. As the
population of patients with chronic, well-controlled HIV infection continues to grow, so
does the overall prevalence of MND, making this manifestation of HAND an important
focus of scientific and clinical investigation. In the CHARTER study, 12% of individuals
met the criteria for MND [33].
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The diagnosis of MND is contingent upon the detection of abnormalities in
neuropsychological testing, specifically with relation to attention, information processing,
learning and memory, psychomotor speed, and executive function [38]. It is distinguished
from ANI because these patients typically experience a subtle, but noticeable, decline in
cognitive ability and increased difficulty in carrying out their activities of daily living.
MND can also manifest through both pyramidal and extrapyramidal motor systems,
producing symptoms such as ataxia, tremor, and incoordination that may worsen over
time [39]. It is also believed that MND can result in behavioral effects, which are
independent from those associated with mood disorders concomitant with HIV infection
[40,41].

HIV-Associated Dementia (HAD)
What was initially described as the AIDS Dementia Complex twenty-five years ago
[20,21] is now known as HIV-Associated Dementia (HAD), the most dramatic
manifestation of HAND [36]. The diagnosis of the condition remains a challenge in
clinical practice, as there are no diagnostic studies or laboratory tests that are specific for
HAD [27,33,36,42]. Therefore, the identification of this disorder is reliant upon the
recognition of a clinical syndrome and the exclusion of alternative diagnoses.
The diagnosis of HAD is based on progressive neurocognitive impairment and the
exclusion of other conditions that can cause or exacerbate such impairment, including
CNS opportunistic infections and tumors. It is further supported by high levels of HIV
RNA in the CSF (typically >3 logs). HAD most typically occurs in patients with slowed
cognitive processing in the context of long-standing HIV infection. Additionally, HAD is
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still most commonly identified in patients off of antiretroviral therapy, with the
prevalence in treated patients estimated to be as low as 2% [34,43-45]. The syndrome is
often characterized by motor abnormalities such as slowed movement and spastic gait, as
well as hyperactive deep tendon reflexes [20]. However, these signs and symptoms are
not diagnostically specific for HAD, and further evaluation with computed tomography
(CT) or magnetic resonance imaging (MRI) is often required. Neuroimaging is most
appropriately used to first rule out more common AIDS-related neurological conditions
including opportunistic infections and CNS lymphoma. With these diagnoses excluded,
diffuse cerebral atrophy and subcortical or periventricular white matter changes are
consistent with, although not specific for, HAD [46-48].

Diagnostic and Management Issues in HAND
Because HAND has no specific markers, it is necessary to rule out CNS opportunistic
infections, neurosyphilis, delirium, toxic-metabolic disorders, psychiatric disease,
delirium, and age-related dementia before making the diagnosis. While traditional
neuroimaging is useful in ruling out other HIV-associated disease processes, including
CNS lymphoma, CNS infections (opportunistic infections and abscesses), and
inflammatory processes, there are no findings on standard neuroimaging with CT or MRI
that are specific for HAND (although more severe disease does present with late-stage
abnormalities on neuroimaging). Recently, an effort has been made to use more advanced
neuroimaging techniques to identify mild HAND. These include brain mapping,
structural imaging, functional MRI assessing brain perfusion and functional connectivity,
and proton-magnetic resonance spectroscopy (proton-MRS), which has shown promise in
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identifying metabolite abnormalities in patients with mild disease [49-62]. Nevertheless,
the utility of these new modalities remains to be determined and the diagnosis of HAND
is therefore reliant upon clinical findings.
Neuropsychological testing results have been shown to improve in the setting of
drug therapy. Early studies of zidovudine (AZT) monotherapy indicated improvement in
testing scores [63,64], and more recent studies have shown that cART decreases HAD
while increasing the prevalence of milder HAND [65,66]. While cART might improve
cognitive performance, this improvement is frequently incomplete and residual deficits
remain [67,68]. There has therefore been a focus on using adjunctive therapy to attenuate
the inflammatory events that are postulated to occur in the CNS of HIV-infected patients
in the hope that this will result in improvements for those with mild HAND.
Efforts have been made to manage HAND with non-antiretroviral adjunctive
therapies including memantine, selegiline, and nimodipine, but none of these have
demonstrated efficacy [69]. Psychiatric drugs like valproic acid and lithium have been
hypothesized to decrease HIV replication and neuroinflammation through their glycogen
synthase-kinase 3-beta activity [70], as have serotonin reuptake inhibitors like citalopram
and paroxitine through an unknown mechanism [70]. However, it remains to be seen
whether these treatment adjuncts will result in improved recovery from HAND.
Similarly, due to anti-inflammatory and antiviral effects, the antibiotic minocycline has
been suggested as a potential therapy for HAND, but randomized studies have not
indicated efficacy [71,72]. Methylphenidate has been successful for symptomatic
management of fatigue [73] and slowing in patients with HAND [74], but this
symptomatic relief does not alter the course of the disease.
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The Etiology of HAND in the Era of Antiretroviral Therapy
Although the biological substrate of HAND in the setting of antiretroviral therapy is
unknown, a number of mechanisms are possible. One potential mechanism is that injury
occurring in the earliest stages of HIV infection is compounded over time and progresses
to clinically detectable abnormalities (i.e., ANI, MND) later in the disease course. Such
injury would begin during the period before treatment is initiated, and would continue
along a trajectory that may or may not be mitigated by initiation of antiretroviral therapy.
After several years, a combination of host susceptibilities and disease factors may result
in the development of symptomatic neurological disease. While this is a plausible
pathogenic mechanism for HAND, data regarding objective neurological injury during
the earliest stages of HIV infection is currently lacking. It is unclear when in the disease
course such injury begins and what the clinical implications of this injury may be.
Another possibility is that, due to the compartment-specific nature of CNS HIV
infection, neurological injury occurs despite the initiation and continuation of
systemically suppressive treatment. Even in individuals with no overt signs or symptoms
of neurocognitive impairment, the presence of HIV in the CNS may result in constant
low-level inflammation and immune activation that has been hypothesized to result in
ongoing brain injury. CSF immune activation, brain inflammation detected by protonMRS, and microglial activation in brain tissue persist in patients on long-term
suppressive antiretroviral therapy started during the chronic stage of infection [25,75-77].
However, much remains unknown regarding the manifestations, etiology, and
implications of compartmentalized HIV infection in patients on suppressive therapy. The
correlates of neurological disease developed in this setting are unclear.
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Below, primary HIV infection and central nervous system compartmentalization
are discussed as potential contributors to neurological disease in patients with HIV. This
background will provide an introduction to the two studies included in this thesis.

The Central Nervous System during Primary HIV Infection
While the study of neurological disease in HIV infection has traditionally focused on
chronic and late-stage neurocognitive manifestations of the virus, recent work has drawn
attention to the effects of HIV on the CNS much earlier in the disease course. Primary
HIV infection, defined as the first year following the transmission of the virus, has been a
focus of this work.
Primary HIV infection is characterized by a rapid and dramatic rise of HIV RNA
levels in the plasma [78-80], accompanied by an increase in HIV antibody levels that are
detectable within 2 weeks of transmission by fourth-generation enzyme immunosorbent
assay (EIA) tests. In at least two-thirds of individuals, the period of seroconversion is
accompanied by the acute retroviral syndrome, characterized by vague symptoms of
fatigue, malaise, fever, and anorexia [78,81]. Within a few months of seroconversion, a
partially effective immune response causes HIV RNA to stabilize at a reduced, chronic,
individual-specific level that serves as the plasma viral “set point” [82]. This is a result of
the increased activity of CD8+ T cells in conjunction with a decreased reservoir of CD4+
T cells available for infection by the virus [83,84]. The standard clinical time course of
HIV infection is reviewed in Figure 2. Note the timing and clinical events of primary
HIV infection, which include the acute retroviral syndrome, dissemination of the virus
and invasion of lymphoid tissues, and the CD4+ T cell nadir.
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Figure 2. Typical time course of HIV-1 infection. Primary HIV infection refers to the first year
following viral transmission, which includes the acute retroviral syndrome, widespread distribution
+
of the virus, the seeding of lymphoid organs, and the CD4 T cell nadir. Patients develop anti-HIV
+
+
cytotoxic T lymphocytes (CTLs or CD8 T cells) as the CD4 T cell count drops, leading to an
+
+
+
increase in the CD8 /CD4 T cell ratio. After a small recovery in the CD4 T cell count, infected
individuals enter a long period of clinical latency in which they experience a slow decline in the
+
+
CD4 T cell population. If treatment is not initiated, the CD4 T cell count falls to critically low
levels and the patient develops AIDS. This period characterized by viral proliferation, increased
risk of acquiring opportunistic infections, and the onset of symptoms consistent with end-organ
damage in a variety of body systems. Ultimately, it leads to death from one or a combination of
these causes. Adapted from Fauci and Desrosiers 1997, Cold Spring Harbor Laboratory Press
[80]. Reproduced with permission from Cold Spring Harbor Laboratory, Retroviruses; reproduced
with permission from Pantaleo et al 1993, NEJM, copyright Massachusetts Medical Society.
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In addition to the symptoms of the acute retroviral syndrome, it has long been
recognized that a subgroup of individuals newly infected with HIV develop neurological
symptoms and signs around the time of seroconversion [85,86]. Evidence suggests that
this occurs in up to 10% of individuals [87]. In addition, HIV can be found in the CSF
and brain tissue of patients during the earliest stages of infection, in the weeks to months
following viral transmission [81,87-89]. Recently, HIV has been identified in the CSF as
early as eight days post-transmission [90], suggesting that this compartment is occupied
by the virus very early in the disease course.
Studies have also shown that immune activation accompanies the presence of
HIV virions in the CSF during primary infection [91]. The elevation in CSF white blood
cell counts, neopterin, and inflammatory cytokines during the first months of infection
suggest the possibility that CNS injury can also take place during this period, contrasting
with the view that the damaging effects of HIV infection occur only after a long period of
clinical latency.
The neurological manifestations associated with early HIV infection vary between
individuals and a consistent underlying pathophysiology remains to be identified. One of
the first syndromes to be linked with HIV infection was “aseptic” meningitis,
characterized by a CSF lymphocytosis or clinical signs of meningitis [92]. Other
individuals experience varying degrees of encephalopathy in the setting of
meningoencephalitis, encephalitis, or encephalomyelitis [93,94]. Acute neuropathies,
including facial nerve paralysis and optic neuritis, also occur frequently with
seroconversion and are common in acute HIV infection [93,94].
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These heterogeneous neurological syndromes associated with primary HIV
infection share several common features. First, the onset is typically within three weeks
following the symptomatic manifestations of the acute retroviral syndrome [85]. Second,
the clinical signs and symptoms are typically self-limited and resolve without any
specific intervention. Third, patients almost always have a seroconversion associated with
the timing of symptoms. Taken together, this suggests that pathogenesis of these
syndromes is likely due to a host-mediated autoimmune response in the setting of
massive systemic immune activation that results from the rapid expansion of the virus in
its new host once transmission has occurred [95].
Seroconversion characterized by a variety of non-neurological symptoms has
been associated with more rapid disease progression [82,83]. Recently, there has been
increased interest in determining whether early HIV infection has neurological
consequences beyond the self-limited symptoms that are associated with the acute
seroconversion syndrome. It remains to be seen whether these early signs of
neuroinflammation related to objective neuronal injury, whether inflammation or injury
predicts neurological outcomes in later stages of the disease, and whether the early
initiation of antiretroviral therapy is able to ameliorate these processes even before
systemic immunosuppression occurs. It is possible, therefore, that the period of primary
HIV infection has important implications for the timing and clinical course of HAND.

HIV Compartmentalization in the Central Nervous System
By separating the CNS from the systemic circulation, the blood-brain and blood-CSF
barriers affect the ability of antiretroviral agents to access the CNS compartment. In
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addition, local spontaneous replication of HIV within this viral sanctuary may allow for
the independent mutation of HIV virions such that the CNS virus “evolves away” from
that in the periphery [4,5,10,12]. While the response of CSF HIV RNA levels to cART
parallels that in the plasma, the rate of decay in the CSF may be more gradual in some
patients [29,96-98], suggesting a compartmentalization characterized by slower cell
turnover, extended macrophage release, or attenuated drug entry into the CNS.
Because of the blood-brain barrier, HIV in the CNS can be protected from the full
effect of antiretroviral agents, especially those that are large or hydrophilic. The CNS
penetration-effectiveness (CPE) index represents an effort to quantitatively estimate the
relative ability of each antiretroviral agent to penetrate the CNS and interfere with CSF
HIV replication. Each agent is assigned a “CPE score,” and a total regimen score can be
calculated by summing the scores for individual agents. The CPE scores for various
agents are reviewed in Table 2 [99].
Some studies have shown that antiretroviral regimens with higher CPE scores
tend to be more successful at achieving HIV RNA suppression in the CNS [100,101].
But, while more potent HIV RNA suppression in this compartment might be expected to
lead to better neurocognitive outcomes and more effective treatment of HAND, this has
not necessarily been the case. Observational studies have suggested that the initiation of
regimens with higher CPE scores may produce a cognitive benefit in patients with HIVrelated neurological disease [102,103], but other studies have shown that HIV-infected
individuals treated with regimens with higher CPE scores actually exhibit poorer
neurocognitive performance despite suppression [101] or only benefit if they are on more
than three drugs, which is the standard for most cART regimens [104].
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CNS Penetration-Effectiveness Score

Drug Class

4

3

2

1

NRT Inhibitor

Zidovudine

Abacavir
Emtricitabine

Lamivudine
Stavudine

Didanosine
Tenofovir
Zalcitabine

NNRT Inhibitor

Nevirapine

Delavirdine
Efavirenz

Etravirine

-

Protease Inhibitor

Indinavir/r

Darunavir/r
Fosamprenavir/r
Indinavir
Lopinavir/r

Atazanavir
Atazanavir/r
Fosamprenavir

Nelfinavir
Ritonavir
Saquinavir
Saquinavir/r
Tipranavir/r

Entry Inhibitor

Vicriviroc

Maraviroc

-

Enfurvirtide

Integrase Inhibitor

-

Raltegravir

-

-

Table 2. Proposed CNS Penetration-Effectiveness (CPE) ranks for commonly used
antiretroviral agents, 2010. NRT = nucleoside reverse transcriptase; NNRT = non-nucleoside
reverse transcriptase; /r = ritonavir boosted. Adapted from Clifford DB at New York, NY: March
22, 2010, IAS-USA [99].
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Recently, the inability of antiretroviral therapy to control the potential reservoir of
HIV that exists in monocytes has been proposed as a possible explanation for continued
neurocognitive impairment in the setting of cART [105]. Along these lines, a monocyte
efficacy (ME) score has been proposed as another means of quantifying the ability of
antiretroviral agents to affect neurological outcomes. Preliminary work using this score
has suggested that that the ME score is a predictor of neurocognitive performance even
when CPE score is not [106]. More work, including prospective studies, is needed to
determine whether ME score is an adequate predictor of neurocognitive outcomes in
patients with HIV.
The effort to classify antiretroviral regimens according to CPE or ME indices
underscores the recognition of CNS HIV compartmentalization as an issue with
important clinical consequences. It is especially important to understand the
heterogeneous manifestations of this compartmentalization as a first step toward
determining whether it might be relevant to or independent of the pathogenesis of HAND
in these patients.

Structure of the Thesis
This thesis is divided into two primary “chapters” that comprise two projects conducted
during 18 months of research on neurological manifestations of HIV infection. Each
chapter focuses on a different process that might be relevant to our understanding of
HIV-associated neurocognitive disorder, as described in the introductory sessions on
primary HIV infection and CNS HIV compartmentalization.
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The first chapter describes a translational research project focused on evidence of
neurological injury in individuals with primary HIV infection. This project involved the
study of CSF and neuroimaging biomarkers of neuronal injury and inflammation in a
cohort of 92 individuals with newly acquired HIV infection and showed for the first time
with these markers that objective neuronal injury occurs at this early time point. This
work has been presented at the International Society for NeuroVirology’s 11th Annual
Symposium on NeuroVirology in May 2012 (appendix 1) and was recently accepted for
publication in the Journal of Infectious Diseases [107].
The second chapter describes a clinical case series investigating a rare but
important manifestation of neurological disease in patients with chronic, well-controlled
HIV infection. This project added a substantial amount of information on the
cerebrospinal fluid and imaging abnormalities in these patients to the limited data that
was already present in the literature. It was presented at the 19th Annual Conference on
Retroviruses and Opportunistic Infections (CROI) in March 2012 (see appendix 2) and
was published in the journal AIDS in September 2012 [19].
Both of these studies are included in the thesis because they represent areas of
HIV disease that have important implications for patients and our understanding of
HAND, but about which relatively little is known. However, because they deal with
fundamentally different time points and pathological processes in the course of HIV
infection, they are better introduced, described, and discussed separately. Afterwards I
will endeavor to synthesize the material from both projects to reach some general
conclusions and discuss future directions of this work.
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CHAPTER 1: CEREBROSPINAL FLUID AND IMAGING BIOMARKERS OF NEURONAL
INJURY IN ANTIRETROVIRAL NAÏVE PATIENTS DURING PRIMARY HIV INFECTION

Chapter Background
As previously discussed, the extent of neurological injury during pre-symptomatic HIV
infection, especially early infection, is not completely understood. Limited data suggest
that neurological injury occurs in some individuals during primary HIV infection, defined
as the first year following viral transmission, during which up to 10% of individuals
develop neurological signs and symptoms and the virus can be detected in CSF and brain
tissue [87]. HIV infiltrates the CSF within days of transmission [90] and immune
activation occurs throughout primary infection [91], suggesting the potential for CNS
injury in the earliest stages of infection.
This chapter describes a research study focused on identifying neuronal injury in
individuals with primary HIV infection, in an effort to further characterize the
neurological implications of the disease beginning at the earliest time point.

Cerebrospinal Fluid Biomarkers
Cerebrospinal fluid biomarkers have gained popularity as objective markers of neuronal
injury in a variety of neurological and neurodegenerative disorders including Alzheimer’s
dementia, Parkinson’s disease, multiple sclerosis, and amyotrophic lateral sclerosis [108113]. Perturbations in the levels of these biomarkers have allowed researchers to
distinguish static neurological abnormalities associated with previous neurological injury
in individuals with HIV infection from active processes associated with ongoing neuronal
injury. Over the last 10 years, there has been an effort to describe the changes in these
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biomarkers that occur with different manifestations of HIV infection in the central
nervous system, including HIV-associated dementia, other manifestations of HAND, and
CNS opportunistic infections.
The biomarkers of interest in the present study are most commonly involved with
neuronal stability and axonal assembly and are described below. Table 3 summarizes the
abnormalities in each biomarker in individuals with HIV and Alzheimer’s disease.

Neurofilament Light Chain
The light subunit of the neurofilament protein is a major structural component of
myelinated axons and has been identified as a sensitive marker of axonal disruption. The
neurofilament protein itself is associated with large myelinated neurons in the cerebral
white matter, and is known for maintaining the caliber of the axon as well as its structural
and functional integrity. In this way, the neurofilament protein is thought to play a crucial
role in the ability of axons to conduct nerve impulses [114].
The light chain of the neurofilament protein has been demonstrated to be a
sensitive marker of neuronal injury in a number of conditions, both chronic and acute.
This includes disorders involving the degeneration of white matter tracts in the brain or
spinal cord, such as amyotrophic lateral sclerosis or multiple sclerosis, as well as cerebral
disorders such as Alzheimer’s disease [110]. In an acute setting, there is a dramatic, dosespecific leakage of neurofilament light chain into the CSF, in proportion to the extent of
ischemic injury [109,115,116].
Neurofilament light chain has been shown to be elevated in HIV-associated
dementia and CNS opportunistic infections, with higher levels associated with worse
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neurological disease [117] (Figure 3). Previously, neurologically asymptomatic HIV-1infected individuals with chronic infection and CD4+ T cell counts above 200 cells/uL
were thought not to have elevated CSF neurofilament light chain, and this threshold was
thought to be sufficient to prevent CNS disease [118]. However, further work in
chronically infected subjects indicated that HIV-infected individuals with CD4+ T cell
counts above 200 cells/uL can have elevations in neurofilament light chain upon the
cessation of cART [119], that lower CD4+ T cell counts tend to be associated with higher
neurofilament light chain [117], and that very low CD4+ T cell counts are associated with
increased neurofilament light chain concentrations [120]. However, neurofilament light
chain was not elevated in the majority of patients with primary infection [117] and its
utility during this time period remained unknown.

Tau Proteins: t-tau and p-tau
Tau is a ubiquitously expressed microtubule-associated protein that promotes axonal
stability and participates in the maintenance of synapses within the central nervous
system [121]. It is largely found in non-myelinated cortical axons [122]. Its
hyperphosphorylated component, known as p-tau, is widely known for its association
with neuronal injury in Alzheimer’s disease, ischemic stroke, and Cruetzfeldt-Jakob
disease [111,123]. It is notably not elevated in Parkinson’s disease [112,124]. Elevated
levels of tau are thought to be related to neuronal loss, which is a characteristic of all of
these conditions; it has been hypothesized that tau levels might reflect the magnitude and
rate of neurodegeneration.
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Figure 3. CSF neurofilament light chain concentrations in 210 HIV-1 infected individuals at
different stages of disease, based on “less-sensitive” assay with lower limit of detection
th
th
250 ng/L. Box plots indicate median values, 25 and 75 percentiles, and ranges. a. Subjects
divided into different groups, showing significant elevations in AIDS Dementia Complex (ADC)
and CNS opportunistic infections (OI), and no elevations in neuroasymptomatic subjects (asympt)
or subjects with primary HIV infection (PHI). b. Subjects with ADC staged according to the
Memorial Sloan-Kettering Scale, indicating elevated neurofilament light chain in more severe
ADC cases. c. Subjects with CNS OIs; CMV encephalitis (CMV-E), CNS lymphomas (CNSL),
cryptococcal meningitis (Crypto), progressive multifocal leukoencephalopathy (PML) and
+
toxoplasmosis (Toxo). d. Neurologically asymptomatic subjects grouped according to their CD4
+
cell counts, showing elevated neurofilament light chain with worsening CD4 T cell counts. From
Abdulle, et al. [117]. Used with kind permission of Springer Science and Business Media.
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Marker

PHI

NFL

=

NA HIV

[117]

[117]

=

[113]

t-tau

No data

=
[139]


p-tau

No data

=
[139]


sAPP-α

No data

=

sAPP-β

No data

=

β-amyloid

No data

=

NAA/Cr

=
[130,131]


Glu/Cr

=

[113]

[123,137]






[117]

[113,125]


[126,127]
=

CNS OI


[117]




[113,123,133,139]

[113]



[113,123,133,139]

=



[113]



[113]

=

[113]



[113]



[113]

=



[113]

[50,59]

[130,136]

[113]

=
[125,139]

[59]

No data

[130,137]

No data




[110]

[113,127]

=

[125]


[113]
=

AD

[113]

[113]

[129,137]

HAND/HAD

[113,123,128]

[113,123,128]



[113,123,128,133,138]



[132,133,134,135]



[134,135]

Table 3. Summary of previously described biomarker perturbations in HIV infection and
Alzheimer’s disease. PHI = primary HIV infection; NA HIV = neuroasymptomatic, chronic HIV
infection; HAD = HIV-associated dementia; CNS OI = central nervous system opportunistic
infections; AD = Alzheimer’s Disease; NFL = neurofilament light chain, sAPP = soluble amyloid
precursor protein; NAA = n-acetylaspartate; Glu = glutamate; Cr = creatine. Reference numbers
provided.

1 = Gisslen 2009 [113]; 2 = Brew 2005 [125]; 3 = Andersson 1999 [126]; 4 = Green 2000 [127]; 5
= Abdulle 2007 [117]; 6 = Andreasson 2007 [128]; 7 = Norgren 2003 [110]; 8 = Blennow 2010
[123]; 9 = Meyerhoff 1993 [50]; 10 = Young 2011 [129]; 11 = Lentz 2009 [130], 12 = Lentz 2011
[131]; 13 = Paul 2007 [59]; 14 = Risacher 2013 [132]; 15 = Chantal 2004 [133]; 16 = Fayed 2011
[134]; 17 = Shinno 2012 [135] ; 18 = Sailasuta 2009 [136]; 19 = Sailasuta 2012 [137]; 20 =
Mawuenyega 2010 [138]; 21 = Clifford 2009 [139]
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Previous studies of tau proteins in HIV infection have been inconclusive in
demonstrating the directionality of perturbations in these metabolites. One recent study
demonstrated t-tau elevations in individuals with HAD, who displayed levels above those
seen in HIV-uninfected controls and neuroasymptomatic HIV-infected individuals [113].
P-tau was not elevated in any CNS manifestations of HIV. The authors suggested that
this was likely due to pathology in neurological HIV infection that more commonly
affects subcortical pathways and does not result in the neurofibrillary tangles common in
Alzheimer’s disease [113]. Other studies have had conflicting results, with some showing
elevated t-tau and p-tau in HAND or HAD [125,126] and others failing to show a
consistent relationship [127,139,140]. Patterns in t-tau and p-tau proteins have not
previously been explored in primary HIV infection.

Proteins of the Amyloid Processing Pathway
The amyloid processing pathway is a complex enzymatic pathway involving the
proteolytic processing of transmembrane proteins that results in the generation of
metabolites with varying pathological potential [128]. Beginning with full-length
transmembrane amyloid precursor protein, the pathway may follow amyloidgenic or nonamyloidgenic routes. In the non-amyloidgenic route, transmembrane amyloid precursor
protein is cleaved by an α-secretase into soluble amyloid precursor protein–α, which is
present in the CSF but does not lead to the formation of pathological β-amyloid. In
contrast, transmembrane amyloid precursor protein might be cleaved by a β-secretase,
which results in the generation of soluble amyloid precursor protein–β. The formation of
this protein results in the production of the β-C-terminal fragment (CTF) protein, which
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in turn is cleaved by a γ-secretase to form β-amyloid peptides. The 1-42 version of βamyloid aggregates to form the amyloid plaques seen in Alzheimer’s disease. The CSF
amyloid profile in Alzheimer’s disease is therefore composed of normal or mildly
elevated CSF sAPP–α and –β proteins with decreased CSF amyloid-beta 42, which
results from increased deposition of the protein in the brain tissue and therefore lower
levels in the CSF [123,128,138].
In HIV-infected individuals, soluble amyloid precursor proteins have been shown
to decrease with late-stage neurological disease, including HIV-associated dementia and
CNS opportunistic infections [113]. However, inconsistencies have been reported in
terms of amyloid-beta 42, with some studies showing no change [113] and others
revealing a decrease consistent with what is found in Alzheimer’s disease [125,139].
Effects on these proteins have not been described during primary HIV infection.

Proton-Magnetic Resonance Spectroscopy
Proton-magnetic resonance spectroscopy (proton-MRS) is a non-invasive imaging
modality that has been used to monitor neuronal injury through the analysis of cerebral
metabolite abnormalities. N-acetylaspartate and glutamate are markers of neuronal health
that deplete with injury [141,142] and are often expressed in terms of their ratio to
creatine. Perturbations in metabolites measured through proton-MRS have been identified
in a number of brain regions of subjects with Alzheimer’s disease [132-137].
Work in macaques suggests that the neuronal manifestations of HIV as identified
through proton-MRS abnormalities occur rapidly but are reversible with the initiation of
cART [143]. In human studies, the N-acetylaspartate/creatine ratio declines in chronic
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untreated HIV infection (i.e., [50,59]), and improves, but does not normalize, with
therapy [144,145].
Some neuroimaging studies have suggested that neuronal injury occurs during
primary HIV infection as evidenced by decreased N-acetylaspartate in the frontal cortex
of newly infected individuals [130,131]. Other studies have failed to find group-level
differences in metabolite levels between controls and patients with primary HIV infection
at baseline [137,138]. Recent work using our cohort of participants with primary
infection has demonstrated that, although there are no group differences at baseline
compared with controls, abnormalities in subjects with primary infection worsen over
time and improve with early initiation of cART [129]. Despite this progress, at the time
of thus study no information linking CSF biomarker data with non-invasive proton-MRS
metabolite data was available.
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Statement of Purpose, Specific Aims, and Hypotheses
In this study, we sought to quantify CSF and neuroimaging biomarkers as a proxy for
neuronal injury in individuals with primary HIV infection and to compare them with
those in HIV-uninfected controls. The specific aims of the study were as follows:
1. To determine whether neurofilament light chain, a sensitive marker of neuronal
injury, is elevated in subjects with primary HIV infection compared with HIVuninfected control subjects.
2. To investigate potential mechanisms of neuronal injury by correlating
abnormalities in neurofilament light chain in primary HIV infection with markers
of CNS inflammation and viral load.
3. To determine whether tau and amyloid proteins are perturbed in primary HIV
infection and to identify relevant correlates of these perturbations.
4. To identify cerebral metabolite abnormalities as measured using proton-magnetic
resonance spectroscopy and to determine whether there is a relationship between
non-invasive imaging and CSF biomarkers of neuronal injury during primary HIV
infection.
5. To examine the relationship between CSF biomarkers of neuronal injury and
neuropsychological testing performance during primary HIV infection.

We hypothesized that primary HIV infection is characterized by increased concentrations
of CSF neurofilament light chain, and that this increase correlates with elevated
concentrations of CSF markers of neuroinflammation and decreased concentrations of Nacetylaspartate and glutamate measured by proton-MRS. We expected tau and amyloid
levels in primary HIV infection to not differ from controls, as has been previously
reported [113] in chronically HIV-infected, neuroasymptomatic individuals.
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Methods
Study Design and Participants
This was a cross-sectional study utilizing clinical signs and symptoms, biological
samples, and laboratory test results from 92 antiretroviral naïve individuals with primary
HIV infection enrolled between 1987 and 2011 at study sites in San Francisco, USA,
Gothenburg, Sweden, and Sydney, Australia.
Participants were referred from physicians or counseling and testing centers based
upon known or suspected recent HIV infection. Participants were eligible if they met
criteria for primary infection based upon nucleic acid testing and less-sensitive ELISA
studies according to the standard serologic testing algorithm for recent HIV
seroconversion, commonly known as the STARHS algorithm [95]. Estimated number of
days post-transmission was calculated assuming exposure occurred 14 days prior to the
acute retroviral syndrome [81], or in the absence of symptoms, as halfway between the
last negative and the first positive test result.
A neurologist screened the participants with a history and physical exam to detect
exclusion criteria including active unrelated neurological disorders such as known prior
stroke, seizure disorder, brain tumor, or CNS opportunistic infections. Subjects were
screened with standardized inventories for comorbid mental illness and substance abuse,
and the presence of these was recorded. Data was excluded from the analysis if
participants demonstrated signs of intoxication and/or reported substance use on the day
of the study visit.
Data regarding CSF HIV RNA and neurological symptoms have been previously
reported in a subset of participants from this study [42,146], as have neurofilament light
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chain results in 16 subjects using a different, less-sensitive assay [117] than the one that
was used in this study.
Twenty-five HIV-uninfected volunteers provided comparison samples. All
participants provided written informed consent in studies approved by the institutional
review board or equivalent entity at each institution.

Specimen Sampling, Processing, and Laboratory Analysis
Participants underwent detailed neurological history and physical examination, as well as
collection of blood and CSF specimens between 7:30am and 12:00pm at study visits. The
timing of specimen collection controlled for potential diurnal variations in amyloid-beta
42 [147]. HIV RNA levels in cell-free CSF and plasma were measured by the
ultrasensitive Roche Amplicor HIV-1 Monitor PCR (version 1.5; Roche Molecular
Diagnostic Systems, Branchburg, NJ), Cobas TaqMan RealTime HIV-1 (version 1 or 2;
Hoffmann-La Roche, Basel, Switzerland), or the Abbott RealTime HIV-1 (Abbot
Laboratories, Abbot Park, IL, USA) assays at local sites. CSF total white blood cells
(WBCs) and protein, and CD4+ and CD8+ T lymphocyte counts were measured on fresh
samples by flow cytometry.
Cell-free CSF and blood plasma were aliquoted and stored within 6 hours of
collection in -70°C or -80°C freezers monitored by National Institutes of Standards and
Technology-certified thermometers. Neurofilament light chain concentration was
measured using a new, highly sensitive, two-site enzymatic quantitative immunoassay
with a lower limit of detection 50 ng/L (UMAN Diagnostics, Umea, Sweden). The uppernormal CSF neurofilament light chain levels at the laboratory were <380 (in subjects <30
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years), <560 (30-39 years), <890 (40-59 years) and <1850 ng/L (>59 years) [148].
Reference values were obtained in the Zetterberg laboratory based on the analysis of 108
neurologically healthy HIV-uninfected individuals. Detection of t-tau, amyloid-beta 42,
and soluble amyloid precursor proteins–α and –β used standard ELISAs. Blood and CSF
neopterin measurements were performed in the laboratory of Dr. Fuchs employing
commercially available immunoassays (BRAHMS Aktiengesellschaft, Hennigsdorf,
Germany); interferon gamma-induced protein 10 (IP-10) and monocyte chemotactic
protein 1 (MCP-1) measurements were performed locally using commercially available
assays (R&D Systems, Minneapolis, USA).

Proton-Magnetic Resonance Spectroscopy
After standard clinical magnetic resonance imaging, proton-MRS was performed on a 4Tesla Siemens/Bruker scanner (Siemens, Erlangen, Germany) in 53 primary HIV
infection participants at baseline in the neuroimaging laboratory of Dr. Meyerhoff.
Water-suppressed short echo-time (TE) single-volume STEAM spectra
(TR/TE/TM=2000/12/10 ms, spectral width=2000 Hz, spectral data size=2048 points,
128 scans, total acquisition time=4:16 min) were acquired from four volumes selected on
sagittal T1-weighted and axial T2-weighted images. Four different tissue types were
targeted: anterior cingulate (20×20×20mm3), frontal white matter (15×25×20mm3), basal
ganglia (17×35×15mm3), and parietal grey matter (25×20×20mm3). Figure 4 shows the
proton-MRS voxel locations of these tissues. We chose these areas based on acute SIV
studies in macaques that had shown changes in these regions [143,149,150].
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Figure 4. Overview of proton-magnetic resonance spectroscopy acquisition locations and
characteristic spectral peaks for metabolites included in this study. Acquired using 4-Tesla
Siemens/Bruker MR system. MI = myo-inositol, Cho = choline-containing metabolites, Cr =
creatine, Glu = glutamate, NAA = N-acetylaspartate. From Young AC at Seattle, WA: March 3,
2012, CROI [129]. Used with permission.
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Meyerhoff and others have previously described most of the proton-MRS
processing methods [151]. Briefly, all MRI and single-volume proton-MRS data were
stored in an SQL database, and were processed and analyzed with updated software tools
developed in-house [152] or in routine use for many years. The spectral fitting software,
SITOOLS, used a parametric model of known metabolite resonances and modeled
spectral components, including those of macromolecules, to fit all spectral resonances
and nonparametric parameters to the baseline. A priori spectral information used the
frequencies, phases, and approximate relative amplitudes of all major metabolites at 4Tesla and also included resonances for macromolecules. The obtained raw metabolite
signal integrals were corrected for MRI-derived tissue and CSF contributions to the
proton-MRS volumes, corrected for different receiver and transmitter settings when
necessary, and then normalized to the cerebral water signal obtained from the
corresponding volumes. For each metabolite, these adjusted signal integrals (“peak
areas”) were converted to metabolite ratios: glutamate/creatine, myo-inositol/creatine, Nacetylaspartate/creatine, and choline-containing metabolites/creatine. We excluded
spectra if they exhibited poor signal-to-noise ratios, excessive water signal, or other
significant artifacts. High-field proton-MRS at 4-Tesla has highly sensitive signal-tonoise detection and allowed us to determine individual peaks of glutamate and glutamine
instead of Glx; this level of resolution is not possible with less powerful magnets.

Neuropsychological Testing
Neuropsychological testing was performed only at the San Francisco site and all
participants were fluent in English. At baseline, a trained psychometrist administered a
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neuropsychological testing battery composed of motor (timed gait, finger tap nondominant hand, grooved pegboard), processing speed (trail making A, digit symbol),
executive function (trail making B, verbal fluency), learning (RAVLT, figural memory),
and memory (RAVLT delay, figural memory delay) domains. To control for the social
and demographic variability in the group, z-scores for neuropsychological testing were
used for all analyses, and were derived from comparing raw scores to age-, gender-,
ethnicity-, and level-of-education-matched norms. We calculated a z-domain score by
averaging all z-scores within that domain, and calculated an NPZ-4 score by summing
grooved pegboard, digit symbol, finger tapping, and timed gait. A total z-score was
calculated as a composite of all tests and a global deficit score was calculated in the
standard manner [153].

Statistical Analyses
Non-parametric descriptive statistics used the Mann Whitney U-test and the KruskalWallis test with post-hoc testing corrected with Dunn’s multiple comparison, all
performed with SPSS (version 19.0, SPSS Inc, Chicago, IL) and GraphPad Prism
(version 5.0d, GraphPad Software, San Diego, USA). Correlations between measured
parameters employed Spearman’s rank correlation coefficient; parametric correlations
and linear regression were also conducted for illustrative purposes. A multivariate
regression model to investigate independent predictors of CSF neurofilament light chain
included age, CSF neopterin, WBC, protein, IP-10, and CSF:plasma albumin ratio; these
parameters had been identified as significant predictors in both the parametric and nonparametric univariate models.
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Results
Study Participant and HIV Disease Characteristics
Table 4 shows background clinical and demographic information for primary HIV
infection participants (n=92) and HIV-uninfected controls (n=25) included in the
analysis. HIV-infected participants were an estimated median of 3.1 months posttransmission and were younger and more likely to be male than the controls. They
displayed the decline in CD4+ T cell count (p<0.0001) and the increased CD8+/CD4+ T
cell ratio characteristic of early HIV infection (p<0.0001) and also demonstrated a CSF
pleocytosis compared with HIV-uninfected controls (p<0.0001). 8/92 (8.7%) participants
in the primary HIV infection group had previously experienced one or more neurological
symptoms during seroconversion, and the majority of participants harbored infection with
HIV-1 subtype B, as described in previous work [42].

CSF Markers of Neuronal Injury during Primary HIV Infection
In a subset of 32 participants, the new CSF neurofilament light chain assay demonstrated
a high degree of correlation with the older, less sensitive assay that was used in previous
studies (r=0.8, p<0.0001). Figure 5 shows comparisons of the six CSF biomarkers in this
study between the primary HIV infection and HIV-uninfected control groups. Median
neurofilament light chain in 82 primary HIV infection participants was elevated
compared with 20 controls (p=0.0004; Figure 5a).
P-tau was elevated in 66 primary HIV infection participants compared with 23
controls (p=0.016, Figure 5b). There were no significant differences between groups in ttau or soluble amyloid precursor proteins–α and –β (Figure 5c-e). Amyloid-beta 42 was
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PHI
n=92

HIV-uninfected
n=25

p-value

95.2%

80%

0.03

Age, years

36 (28-46)

43 (40-49)

0.001

Estimated Days of Infection

% Male

92 (52-152)

-

-

+

536 (392-682)

836 (703-1056)

< 0.0001

+

985 (161-9063)

550 (157-1031)

< 0.0001

Log10 Plasma VL

4.6 (4.0-5.2)

-

-

Log10 CSF VL

2.9 (2.0-3.6)

-

-

CSF Protein, mg/dL

41 (32-53)

47 (33-56)

0.71

CSF WBC, cells/uL

6 (2-11)

1 (0-2.5)

< 0.0001

8.7%

-

-

CD4 Count, cells/uL
CD8 Count, cells/uL

% ARS Neuro Symptoms

Table 4. Demographic and descriptive characteristics of primary HIV infection participants
and HIV-uninfected controls. Values are shown as median (IQR) except where noted. PHI =
primary HIV infection; VL = viral load; CSF = cerebrospinal fluid, WBC = white blood cells, ARS =
antiretroviral syndrome. Used with permission [107].
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Figure 5. CSF biomarkers of neuronal injury in the primary HIV infection group and HIV-uninfected control group. Note the statistically
significant elevations in NFL, p-tau, and amyloid-beta 42. PHI = primary HIV infection group, HIV- = HIV-uninfected control group, NFL =
neurofilament light chain, p-tau = hyperphosphorylated tau, t-tau = total tau, sAPP = soluble amyloid precursor protein. Used with permission
[107].
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elevated in 73 primary HIV infection participants compared with 23 controls (p=0.0005;
Figure 5f).
Figure 6a indicates that, when stratified by age, 36/82 (44%) participants had
neurofilament light chain elevations above the upper limit of normal for their age group:
13/24 (54%) <30 years, 12/24 (50%) 30-39 years, 10/31 (32%) 40-59 years, and 1/3
(33%) >59 years. Figure 6b-c shows that participants who had experienced neurologically
symptomatic seroconversion (n=8) did not have higher neurofilament light chain,
amyloid-beta 42, or p-tau (not shown) than those who had been neurologically
asymptomatic during seroconversion. Even when previously symptomatic participants
were excluded, these biomarkers remained elevated in the primary infection group
compared with controls.

Determinants of Elevated Neurofilament Light Chain during Primary HIV Infection
Figure 7 displays the correlations between neurofilament light chain and markers of viral
and immune system activity in the CSF. CSF neurofilament light chain correlated with
concentrations of inflammatory markers including CSF neopterin (r=0.38; p=0.0005) and
IP-10 (r=0.39; p =0.002), WBC count (r=0.32; p=0.004), protein (p=0.59; p<0.0001) and
CSF:plasma albumin ratio (r=0.60; p<0.0001). Significant correlations were not found
between neurofilament light chain and CD4+ T cell count, estimated days post-infection
at sampling, plasma and CSF HIV RNA levels, or CSF MCP-1 (p=0.33; graph not
shown).
Figure 8 shows the relationship between neurofilament light chain concentrations
and metabolite analyses conducted with proton-MRS. Elevated levels of neurofilament
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Figure 6. Biomarker measurements stratified by age and history of symptomatic
seroconversion. a. CSF neurofilament light chain measurements stratified by age, with relation
to the age-specific upper limit of normal. 44% of subjects have elevations above the upper limit of
normal for their age group. b. CSF neurofilament light chain values stratified by history of
symptomatic seroconversion, showing significant elevations regardless of presence or absence of
previous neurological symptoms. c. CSF beta-amyloid values stratified by history of symptomatic
seroconversion, showing significant elevation even when previously symptomatic patients are
removed. NFL= neurofilament light chain, PHI = primary HIV infection.
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Figure 7. Selected correlates of neurofilament light chain levels in primary HIV infection. r
represents the Spearman correlation coefficient and the corresponding p-value is displayed. Solid
lines represent best-fit regression line and dashed lines represent 95% confidence intervals.
Used with permission [107].

46

light chain correlated with low N-acetylaspartate/creatine and glutamate/creatine ratios in
the anterior cingulate (r=-0.35, p=0.02; r=-0.40, p=0.009, respectively), frontal white
matter (r=-0.43, p=0.003; r=-0.30, p=0.048, respectively), and parietal gray matter (r=0.43, p=0.003; r=-0.47, p=0.001, respectively). Figure 9 demonstrates that Nacetylaspartate/creatine and glutamate/creatine ratios were correlated across these three
brain regions (r>0.50, p<0.001). No significant correlations were present between
neurofilament light chain and glutamate/creatine or N-acetylaspartate/creatine in the
basal ganglia (Figure 8g-h) or with myo-inositol/creatine or choline/creatine from any
region (data not shown).
Multivariate linear regression modeling was used to identify independent
predictors of CSF neurofilament light chain in primary infection participants and revealed
independent correlations with age, CSF WBCs, and CSF:plasma albumin ratio (adjusted
r-square=0.624).

Determinants of Elevated Amyloid-beta 42 during Primary HIV Infection
Figure 10 shows correlations between amyloid-beta 42 and CSF markers of HIV disease
and neuroinflammation. Amyloid-beta 42 did not correlate with age in the primary HIV
infection group, but did correlate with levels of soluble amyloid precursor proteins–α and
–β (r=0.27, p=0.03; r=0.30, p=0.015, respectively) and with estimated days post-infection
(r=0.34, p=0.003). There were no significant correlations between amyloid-beta 42 and
plasma or CSF viral load, CSF:plasma albumin ratio or CSF protein, neopterin, MCP-1,
or IP-10. Notably, neurofilament light chain and amyloid-beta 42 did show a modest
correlation (r=0.29, p=0.018; Figure 10g).
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Figure 8. Correlations of neurofilament light chain levels with regional proton-magnetic
resonance spectroscopy-derived metabolite ratios. r represents the Spearman correlation
coefficient and corresponding p-value. Solid lines represent best-fit regression line and dashed
lines represent 95% confidence intervals. Used with permission [107].
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Figure 9. Correlations between N-acetylaspartate/creatine and glutamate/creatine
measured by proton-magnetic resonance spectroscopy in selected brain regions. Note the
high level of correlation across the three regions. r represents the Spearman correlation
coefficient and the corresponding p-value is displayed.

49

Figure 10. Selected correlates of amyloid-beta 42 in primary HIV infection. r represents the
Spearman correlation coefficient and the corresponding p-value is displayed. Solid lines
represent best-fit regression line and dashed lines represent 95% confidence intervals. Used with
permission [107].
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Neuropsychological Testing in Primary HIV Infection Participants
Figure 11 shows the results of neuropsychological testing in the primary HIV infection
cohort at baseline and compares the mean for the HIV-infected group to a theoretical
mean of 0 (normal neuropsychological performance). Overall, the primary HIV infection
subjects did not differ from the theoretical mean in motor performance (mean -0.16;
p=0.10) but performed worse than would be expected on tests of executive function
(mean -0.44, p<0.0001), processing (mean -0.53, p<0.0001), memory (mean -0.39,
p=0.0001), and learning (mean -0.61, p<0.0001).
Figure 12 shows the relationship between neuropsychological testing performance
and neurofilament light chain measurements. There were no significant correlations
between CSF neurofilament light chain and composite z-scores for motor function,
processing speed, memory, or learning. Neurofilament light chain and the composite zscore for executive function tended to be correlated (r=0.27; p=0.049). There was no
evidence of correlation between neurofilament light chain and the global deficit score.
There were no significant correlations between amyloid-beta 42 or p-tau and any
composite z-scores on neuropsychological testing (data not shown).

Discussion
The findings in this study demonstrate that several biomarkers of neuronal injury,
including neurofilament light chain and amyloid-beta 42, are abnormal in the CSF of a
subset of individuals with primary HIV infection and that neurofilament light chain
concentration correlates with established proton-MRS markers of neuronal injury. This
suggests that neuronal injury, in addition to viral replication [87], immune activation
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Figure 11. Neuropsychological testing performance at baseline (median of 3.1 months) in
participants with primary HIV infection. “0” line indicates control z-domain score. Z-domain
scores calculated as average of z-scores for each component of the domain (see text for domain
components), with each z-score increment representing 1 standard deviation above or below 0.
Bars represent mean and standard deviation for each component. P-values calculated using a
one-sample t-test with theoretical mean of 0.
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Figure 12. Correlations between composite domain-based neuropsychological testing performance and neurofilament light chain
concentration in subjects with primary HIV infection. r represents the Spearman correlation coefficient and the corresponding p-value is
displayed.
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[29,154], and blood-brain barrier breakdown [87] occurs early in the course of HIV

infection in some individuals.
The association of neurofilament light chain with markers of inflammation
suggests a relationship between injury and immune activation in this setting. The finding
that proton-MRS measures of cortical and white matter N-acetylaspartate/creatine and
glutamate/creatine demonstrate associations with CSF neurofilament light chain
concentrations is the first data to relate non-invasive neuroimaging markers of neuronal
injury (i.e., proton-MRS) with CSF neural marker abnormalities in HIV infection.
Neuronal health and stability appears compromised in some brain regions,
including the frontal white matter and parietal gray matter, in the earliest stages of HIV
infection. The lack of a convincing correlation between neurofilament light chain levels
and performance on common neuropsychological tests may suggest that neurofilament
light chain elevation reflects subclinical injury during this stage of infection, but may also
reflect shortcomings with regard to the sensitivity and/or specificity of
neuropsychological testing during this time period.

Neurofilament Light Chain
Neurofilament light chain concentration serves as a sensitive indicator of CNS axonal
injury in a number of neurodegenerative disorders including Alzheimer’s disease,
atypical Parkinsonian syndromes, and amyotrophic lateral sclerosis [110,123], as well as
in multiple sclerosis [108] and traumatic brain injury [155]. CSF neurofilament light chain
concentrations increase in untreated individuals with HIV-associated dementia and
neurological opportunistic infections [117]. Moreover, neurofilament light chain may
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predict who goes on to develop neurological disease [156], has been shown to decrease
with the initiation of antiretroviral therapy [118], and increases with cART
discontinuation [119]. This previous data suggests that neuronal damage occurs in the
setting of the pathogenic activity of HIV in the central nervous system and the immune
response of the host during other stages of HIV infection.
Previous work including a subset of patients from this cohort identified elevated
neurofilament light chain in 4/16 (25%) subjects with primary HIV infection, but showed
no significant difference compared with controls [117]. However, that work utilized a
less-sensitive assay, with a lower limit of detection of 250 ng/L compared with the assay
used in this study, which had a lower limit of detection of 50 ng/L. The two assays had a
strong correlation when results were compared in a subset of subjects, but the newer,
more-sensitive assay allowed for greater resolution of the lower end of the concentration
scale and resolved points that were previously clustered together at the lower limit of
detection using the earlier assay.
Our findings using this more-sensitive assay demonstrate increased neurofilament
light chain in the group comparison, which has not previously been demonstrated in
primary HIV infection [117]. The results also demonstrate that 44% of participants in this
study had elevations in neurofilament light chain above the age-appropriate upper limit of
normal for this marker. This finding suggests that, in at least a subset of participants,
neurological injury occurs during primary HIV infection even in subjects who had not
previously experienced neurological symptoms during seroconversion. Along with CSF
HIV RNA and inflammatory markers, elevated neurofilament light chain levels may help
to identify individuals with an active disease process and distinguish them from those
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with static neurological abnormalities. Since it has been suggested that neurofilament
light chain can predict neurologic disease progression [156], it is possible that this marker
may identify individuals that could benefit from early pharmacologic intervention aimed
at protecting the brain from neuronal injury.
It is also worth noting that a significant proportion of these participants (56%) did
not demonstrate elevated neurofilament light chain, suggesting the possibility that an
unknown viral or host factor increases the susceptibility of certain individuals to
neurological injury during this period.

Correlates of Elevated Neurofilament Light Chain during Primary HIV Infection
Overall, the results of this analysis suggest an association between neurofilament light
chain and inflammatory processes in the central nervous system, reflected in significant
correlations with CSF neopterin and IP-10, as well as markers of CSF pleocytosis and
blood-brain barrier breakdown. It is notable that such associations did not exist with
amyloid-beta 42, implying that neurofilament light chain might be a more specific marker
for inflammatory injury in the central nervous system.
During primary infection, neurofilament light chain was not associated with CD4+
T lymphocyte count, which may reflect the fact that CD4+ count during this period is a
correlate of the acute systemic immune response to HIV acquisition rather than the
duration and progression of infection. Neurofilament light chain also did not strongly
associate with markers of infection, including plasma and CSF HIV RNA.
Because the N-acetylaspartate/creatine ratio is a putative marker of neuronal
health, our results suggest that declining neuronal health is associated with increased
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neuronal injury as identified through elevated CSF neurofilament light chain. This is
particularly true in the parietal gray matter and frontal white matter, consistent with
studies in animal models [149,150]. We also found a negative association between the
glutamate/creatine ratio and neurofilament light chain. Elevated glutamate/creatine is a
putative marker for excitotoxicity, but it is also considered a marker of neuronal integrity
(i.e., [142]). Previous studies have shown that HIV-infected individuals with cognitive
deficits have lower glutamate/creatine levels, particularly in the parietal gray matter but
not the frontal white matter [142]. Here, we found a similar regional specificity in that
high neurofilament light chain levels correlated strongly with low glutamate/creatine in
the parietal gray matter, but not in the frontal white matter. The strong correlations
between glutamate/creatine and N-acetylaspartate/creatine ratios across all brain regions
emphasize the value of these metabolites in the assessment of neuronal health and
suggest that the consistent regional metabolite correlations with neurofilament light chain
are meaningful.
It is difficult to draw clear conclusions from the generally below-average
performance on the tests for many neuropsychological domains, because performance on
these tests may be confounded by a variety of factors related to HIV infection but
unrelated to the pathogenesis of the disease. In addition, we found no convincing
correlation between CSF neurofilament light chain and performance on most cognitive
domains assessed by this circumscribed battery of tests. However, a modest association
between higher NFL and poorer performance in tests of executive function may reflect a
relationship between neural injury and impairment of this cognitive domain during early
infection.
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Tau Proteins
Tau and amyloid proteins are valuable in the identification of neurodegenerative
disorders [138,157,158], but their utility in HIV infection is less clear. T-tau and p-tau
patterns in HAND and HAD are inconsistent [113,125,140].
In this study, elevated p-tau occurred in the context of unchanged t-tau, a pattern
different from that which is seen in chronic AIDS [125], Alzheimer’s disease [158], and
Creutzfeldt-Jakob disease [159]. The difference is weaker than that identified for
neurofilament light chain or amyloid-beta 42, and we are therefore unable to conclude
from this study whether t-tau and p-tau could be useful measures of neuronal injury in
primary HIV infection.

Amyloid Proteins
Amyloid precursor proteins are cleaved by secretases into soluble amyloid precursor
proteins–α and –β; cleavage to –β form generates a molecule leading to amyloid-beta 42
[113,128]. Amyloid-beta 42 decreases in Alzheimer’s disease [138] and in HAND [139],
HAD [125], and CNS Opportunistic Infections [113]. Pathological studies show amyloid
deposition in brain tissue of HIV-infected individuals [160], but this marker has not been
explored in primary HIV infection.
The elevation in amyloid-beta 42 discovered here could be accounted for by a
number of mechanisms. It is unlikely to be due to the age of the participants in each
group, as median levels for controls is concordant with those for young controls in other
studies [113], and the median value in primary HIV infection participants is higher than
in neuroasymptomatic HIV-infected individuals [113].
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Elevated CSF amyloid-beta 42 has recently been associated with cerebral
inflammation [161] and this elevation is associated with increases in markers of
inflammation in the CSF, including TNF-α, IL-6, and IL-8. This suggests that acute
cerebral inflammation results in the production of amyloid-beta 42. While our primary
infection subjects presented with a neuroinflammatory picture (with elevated CSF WBCs,
IP-10, and protein), amyloid-beta 42 did not correlate with markers of neuroinflammation
in this group. However, the markers we measured differed from those for which
correlations have been identified (TNF-α, IL-6, or IL-8) in other studies [161].
There are a number of other mechanisms that may cause or be associated with this
unexpected elevation of amyloid-beta 42. In the plasma, a large fraction of this protein is
bound to and transported by albumin [162]. The disruption of the blood-brain barrier in
primary HIV infection may cause a translocation of amyloid-β-albumin complexes into
the CSF [91], but we found no correlation between amyloid-beta 42 and CSF:plasma
albumin ratio, which is a marker of blood-brain barrier breakdown. Low-density
lipoprotein receptor-related protein (LRP) clears soluble amyloid-beta 42 by mediating
endocytosis in macrophages [163], which go on to catabolize this protein. HIV tat protein
inhibits LRP uptake and degradation of amyloid-beta 42 [164] and increases its
intracellular, soluble component [165]. It is possible that viral replication in primary HIV
infection results in tat-mediated inhibition of amyloid-beta 42 uptake and degradation
within macrophages, which are known to be infected early by the virus [166]. While there
was no correlation between amyloid-beta 42 and viral load, tat protein may be produced
in such quantities during primary infection that the viral load itself is not the determinant
of inhibited amyloid degradation.
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Limitations
This cross-sectional study captured participants at a single time point; future work with
longitudinal data from this group will help to determine how these biomarkers change
with time. Our study participants were almost exclusively men, which poses a problem
for generalizing these results to the increasing number of HIV-infected women. Because
the median duration of infection was 3.1 months, it is unclear when during primary HIV
infection these biomarker abnormalities begin to occur.
We defined our hypotheses before conducting our analyses, but still made many
statistical comparisons; because of this, we attempted to exercise restraint in statistical
interpretation and to correct for multiple comparisons. Nevertheless, we find the data,
particularly in the contrasts in correlated variables between neurofilament light chain and
amyloid-beta 42, to be a convincing starting point for further exploration of the
mechanisms of neurologic injury during primary HIV infection.
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CHAPTER 2: CEREBROSPINAL FLUID HIV “ESCAPE” ASSOCIATED WITH PROGRESSIVE
NEUROLOGICAL INJURY IN PATIENTS ON ANTIRETROVIRAL THERAPY WITH WELLCONTROLLED PLASMA VIRAL LOAD

Chapter Background
As discussed in the Introduction, the mechanisms and clinical implications of
compartmentalization of HIV within the central nervous system is an area of growing
scientific interest. This chapter focuses on a newly identified manifestation of this
compartmentalization, which has recently been recognized as having important
implications for patients with well-controlled, chronic HIV infection and may be help us
understand the mechanisms behind HAND in the antiretroviral era.

CSF ‘Escape’
Recently, Canestri et al. demonstrated the phenomenon of CSF/plasma HIV RNA
discordance involving the development of new neurological symptoms in eleven patients
with well-controlled plasma HIV [18]. These patients, in general, had chronic HIV
infection managed long-term with antiretroviral therapy and went on to develop
symptoms despite having a relatively well-controlled plasma viral load. In all cases, it
was noted that although the virus was controlled or suppressed in the plasma, these
patients had virus present at a concentration of 1 log greater in the CSF. Further
investigation revealed that, in some cases, significant resistance mutations in the CSF
viral subpopulation were present on genotyping. This suggested that the current treatment
regimen had failed in the CNS despite its success in the plasma compartment. Some
patients improved when their antiretroviral therapy regimen was optimized based upon
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the results of genotyping and the analysis of presumed CNS drug exposure as measured
through the CPE score.
This work has suggested that even in the setting of long-term plasma viral control,
a subset of patients may go on to develop neurological symptoms because of a failure of
control in the CSF compartment. Laboratory studies in these patients have revealed lowlevel viremia in the CSF in the setting of suppressed plasma HIV RNA and relatively
preserved immune function. This phenomenon of CSF ‘escape’ was initially reported in
individual cases [167-170] and culminated with the Canestri report. However, despite
these publications, CSF ‘escape’ remains a poorly understood phenomenon. This is
largely due to some of the criticisms of previous reports, in which some patients have
been on monotherapy [18] or salvage therapy [167,168], or have had low CD4+ T cell
counts [18,169]. Imaging data has been generally sparse and information on follow-up
has been limited.
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Statement of Purpose, Specific Aims, and Hypotheses
In this project, we sought to add to the contributions of Canestri et al. [18] and previous
reports [167-170] by further investigating the condition of CSF ‘escape’ in patients with
well-controlled plasma HIV and preserved immune function. We also sought to provide
more detailed background information regarding HIV disease course in these patients and
to emphasize key portions of the clinical picture, including neuroimaging, that have not
yet been described in detail. The specific aims of this project were as follows:
1. To identify cases of CSF ‘escape’ according to a strict case definition that
excludes patients who have been generally non-compliant with mediations, have
been on unusual or incomplete regimens, or have an unknown disease history.
2. To characterize these cases in terms of patient demographics and disease history,
including nadir CD4+ T cell count, HIV plasma viral load, neurological signs and
symptoms, and antiretroviral regimen.
3. To characterize the cerebrospinal fluid and imaging findings in these patients.
4. To investigate antiretroviral resistance patterns and CNS penetration efficacy of
regimens before and after CSF escape was identified.
5. To hypothesize host and disease mechanisms contributing to the development of
CSF HIV ‘escape.’

In this chapter, we report a group of patients from four institutions in the United States
and Europe. Each patient presented with new-onset neurological symptoms in the context
of low or undetectable plasma HIV levels, underwent neurological studies including
lumbar puncture and CSF analysis, and was noted to have CSF ‘escape.’ Antiretroviral
therapy regimens were optimized based upon drug susceptibility and penetration as
measured through resistance genotyping and CPE. This study adds to a growing body of
evidence regarding the rare condition of CSF ‘escape’ associated with progressive
neurological disease in otherwise well-controlled HIV infection.
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Methods
Study Initiation
In July 2011, a patient (patient 1000) was referred by his primary care HIV provider
(N.A.) and was seen in HIV neurology clinic by two of the authors (M.J.P. and S.S.). The
patient had been diagnosed with HIV in 1990 and had been compliant with medications,
as evidenced by low (<50 copies/mL) or undetectable viral loads throughout most of the
time since diagnosis. He presented with a complaint of worsening headaches and
intractable vertigo. A complete workup, including lumbar puncture, revealed that the only
laboratory abnormality was slightly elevated CSF HIV RNA level (460 copies/mL) in the
setting of <50 copies/mL in the plasma. An exhaustive investigation for other
contributing comorbidities, including opportunistic infections, did not reveal any
additional contributing factors. The patient was diagnosed with CSF/plasma discordance.
A literature review of the case presentation revealed few publications on this
topic. Upon further discussion with the patient’s primary clinician, she recalled one other
case from the Nathan Smith Clinic. We conducted a review of the previous case and
identified it as another example of CSF/plasma discordance or CSF ‘escape.’ It was
decided to assemble a case report and to identify similar cases among our research
collaborators. Consent was obtained from patients to have their data included in a report.
We drafted a screening protocol for distribution to collaborators in the United
States and Europe. This protocol defined a case as “generally well-controlled HIVinfected patients on antiretroviral therapy presenting with neurological symptoms in the
setting of previous viral suppression who are determined to have detectable CSF viral
load on lumbar puncture.” We requested information on disease factors, medication
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regimen, CSF studies, brain imaging, EEG, and initial consult and follow-up notes (see
appendix 3). These materials were requested electronically and in person at trips to
collaborating institutions, where additional visits were scheduled with patients if they
were still being followed. All material was compiled in a central repository at Yale.

Study Design and Patient Characteristics
In this study, we retrospectively compiled cases of HIV-infected patients on antiretroviral
therapy who presented with neurological signs and/or symptoms in the context of plasma
HIV RNA suppression and underwent evaluation, including CSF studies. Subjects were
identified by clinicians in our research collaboration at four urban academic centers in
San Francisco, USA, Milan, Italy, New Haven, USA, and Gothenburg, Sweden.
All patients were on stable combination antiretroviral therapy regimens with
either suppressed (<500 copies/mL) or undetectable (<50 copies/mL) plasma HIV RNA.
Patients with symptoms attributable to other neurologic or psychiatric causes were
excluded. CSF and concurrent plasma samples were obtained either by the primary
clinical team for diagnostic purposes or in the context of research studies in separate local
protocols that were approved by the institutional review board or local equivalent at each
institution. Clinical brain MRIs were obtained prior to lumbar puncture on varied local
1.5-Tesla scanners in the majority of subjects. We included patients found to have CSF
‘escape,’ defined as detectable CSF HIV RNA in the setting of plasma levels <50
copies/mL or CSF RNA >1 log higher than plasma RNA level as previously defined by
Canestri and colleagues [18].
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Laboratory and Statistical Methods
HIV RNA levels were measured in cell-free CSF and plasma using the ultrasensitive
Amplicor HIV Monitor (version 1.5; Roche Molecular Diagnostic Systems, Branchburg,
NJ), Cobas TaqMan RealTime HIV-1 (version 1 or 2; Hoffmann-La Roche, Basel,
Switzerland), or the Abbott RealTime HIV-1 (Abbot Laboratories, Abbot Park, IL, USA)
assays at local sites. For uniformity, 50 copies/mL was used as the lower limit of
quantitative detection in this analysis. Paired blood and CSF measurements used the same
assay. CSF total WBCs and protein, and CD4+ and CD8+ T lymphocyte counts by flow
cytometry were measured at each local laboratory on fresh samples. Blood and CSF
neopterin measurements employed commercially available immunoassays (BRAHMS
Aktiengesellschaft, Hennigsdorf, Germany) and were performed in one laboratory. HIV
resistance genotyping was performed where available in CSF samples harboring adequate
HIV RNA levels for amplification. Genotyping was interpreted according to the
International Antiviral Society-USA guidelines [171].
As a means to approximate expected effectiveness of ART in the CNS, we used
proposed CNS penetration-effectiveness (CPE) scores using the 2010 version developed
by Letendre and colleagues [33] to calculate a “raw” CPE score for each regimen at the
time when discordance was identified. These are reviewed in Table 2. In an effort to take
into account effective resistance in a consistent, quantitative way, we calculated an
“adjusted” CPE score based upon the genotyping results of CSF viral isolates. When a
mutation to a particular drug in the regimen was identified, the individual CPE score for
that drug was arbitrarily designated “0” so that its contribution to the regimen would
effectively be removed from the calculation.
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Descriptive analyses were undertaken to characterize these patients and are
reported as percentages or median value (range) for continuous variables.

Results
Between February 2000 and August 2011, 10 patients with chronic but well-controlled
HIV infection and preserved immune status presented with new neurological symptoms
and were recognized as meeting the criteria for CSF ‘escape.’ The clinical and
demographic characteristics of these patients are described in Table 5.
The patients consisted of 8 men and 2 women with a median age of 47.5 years
(range, 26-55 years). The median time since HIV diagnosis was 16.2 years (range, 9.421.7 years). At the time of the neurologic episode, the patients had been on a stable
regimen for a median of 21 months (range, 9-60 months). These regimens consisted of at
least 2 NRTIs plus a PI in 9/10 cases; the PI was boosted with ritonavir in 8/9 cases.
Individual patients had additional components to their regimen, including integrase or
fusion inhibitors. None were on mono- or dual-therapy.
The median duration of HIV RNA suppression below 500 copies was 27.5
months (range, 2-96 months). The median duration of HIV RNA suppression below 50
copies was 19.5 months (range, 2-96 months). The median CD4+ T cell count at
presentation was 482 cells/mm3 (range, 290-660 cells/mm3). The median nadir CD4+ T
cell count was 35 cells/mm3 (range, 4-222 cells/mm3).
Three patients had a previous neurological abnormality. These included a
presumed cerebellar meningioma that had been stable for many years (patient 1000),
labyrinthitis and right sensorineural deafness (patient 8000), and CNS lymphoma that had
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Historical Data
Nadir CD4+
Documented time
T cell count
stable plasma HIV†
3
(cells/mm )
(copies/mL: months)

CD4+
T cell count
(cells/mm3)

Date of
Presentation
(month/year)

Age/Sex
(years)

SF
7066

02/2000

45/M

55

<50: n/a
<500: 23

318

MI
9000

05/2003

46/F

15

<50: 28
<500: 28

305

SF
1034

03/2004

51/M

80

<50: 2
<500: 2

588

SF
7071

07/2004

49/M

8

<50: 30
<500: 30

444

SF
4065

02/2007

49/M

4

<50: 2
<500: 7

520

NH
2000

03/2007

55/M

60

<50: 96
<500: 96

308

GS
5168

05/2008

45/F

55

<50: 47
<500: 60

660

MI
8000

08/2010

45/M

222

<50: 27
<500: 27

545

MI
7000

01/2011

26/M

9

<50: 4
<500: 12

290

NH
1000

08/2011

49/M

180

<50: 12
<500: 43

627

Site*
Patient

Time of Presentation
Plasma
HIV RNA
Drug
Neurologic
(copies/mL)
regimen
Signs/Symptoms
DDI
Cognitive impairment
380
SGC
Gait ataxia
RTV
3TC
Coma
372
d4T
Tremor
LPV/r
Vertigo
Cognitive impairment
3TC
Gait ataxia
<50
ZDV
Tremor
LPV/r
Weakness
3TC
ZDV
Cognitive impairment
EFV
Gait ataxia
<50
LPV/r
Sensory impairment
T-20
Cognitive Impairment
DDI
Diplopia
184
TDF
Dysphagia
ATV/r
Gait ataxia
Aphasia
3TC
Gait ataxia
<50
ABC
Sensory impairment
LPV/r
Tremor
3TC
118
TDF
Cognitive impairment
ATV/r
Cognitive impairment
3TC
Dysarthria
<50
ABC
Sensory impairment
FPV/r
Vertigo
Diplopia
FTC
Dysarthria
98
TDF
Gait ataxia
ATV
Headache
Tremor
FTC
Aphasia
TDF
Cognitive impairment
ATV/r
Gait ataxia
<50
RAL
Headache
Vertigo

Table 5. Demographic information and HIV history of patients with CSF/plasma discordance. SF = San Francisco; MI =
Milan, Italy; NH = New Haven; GS = Gothenburg, Sweden; n/a = not applicable; * = site-specific research protocol identifiers are
provided where available; † = where <500 copies/mL is considered “good control” and <50 copies/mL is considered
“undetectable,” length of time <500 copies/mL includes times when patient was <50 copies/mL. See table 7 for drug abbreviations.
Used with permission [107].
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resolved completely with initiation of ART, without radiotherapy, several years before
(patient 5168).

Clinical and MRI Manifestations
The neurological abnormalities present in this patient group (Table 5) occurred subacutely (>2 weeks) in 9/10 patients and were acute (<2 weeks) in 1 patient (patient 9000).
They comprise a variety of sensory (in 3 patients), motor (in 9 patients), and cognitive (in
8 patients) manifestations. Imaging in 7/8 patients at the time of presentation showed
MRI abnormalities consisting of white matter hyperintensities on T2-weighted and
FLAIR sequences (Table 6). Figure 13a-d shows representative imaging examples from
patients 2000 and 7000 during the initial studies for neurologic symptoms.

CSF and Brain Pathology
CSF pleocytosis and biochemical abnormalities were found in all 10 patients (Table 6).
8/9 patients had elevated CSF protein levels ≥ 60 mg/dL. The median protein level was
105 mg/dL (range, 46-170 mg/dL). CSF pleocytosis was observed in 9/10 patients, with
median 14.5 cells/mm3 (range 0-200 cells/mm3). All samples were negative for bacteria,
fungi, and other viruses by standard microbiological tests at each institution, including JC
virus DNA studies for progressive multifocal leukoencephalopathy (PML). Two samples
(patients 1000 and 7000) had low-level (<5000 copies/mL) EBV DNA [172]. CSF from
patient 5168 had previously been positive for EBV in the past when she suffered from
CNS lymphoma, but CSF EBV titers were negative during and throughout the time of
CSF HIV escape in this patient.
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Cerebrospinal Fluid Analysis
Plasma HIV
RNA
(copies/mL)

HIV RNA
(copies/mL)

Protein
(mg/dL)

WBC
(cells/mm3)

CSF
Neopterin
(nmol/L)

380

9056

162

50

76.3

MI
9000

372

8000

170

0

-

Diffuse white matter abnormalities

SF
1034

<50

378

89

6

-

Patchy periventricular white matter abnormalities

SF
7071

<50

8320

60

33

-

Not done

SF
4065

184

4570

74

14

-

Patchy subcortical/ periventricular white matter abnormalities with
involvement of corpus collosum and cerebellum

NH
2000

<50

613

77

28

-

Symmetric subcortical/ periventricular white matter abnormalities
extending into cerebellum

GS
5168

118

3230

n/a

9

37.6

MI
8000

<50

134

121

15

-

Diffuse white matter abnormalities

MI
7000

98

5200

137

200

-

Lenticular/posterior internal capsule/cingular cortex white matter
abnormalities extending into cerebellum; diffuse pial contrast
enhancement

NH
1000

<50

460

46

11

-

Cortical/subcortical/periventricular white matter abnormalities

Site
Patient
SF
7066

MRI Findings
Not done

Slight deformity of frontal ventricular horns, stable compared to
previous examinations. Otherwise normal.

Table 6. Neurological studies in patients with CSF/plasma discordance. WBC = white blood cells; SF = San Francisco; MI = Milan, Italy; NH =
New Haven; GS = Gothenburg, Sweden; n/a = not available. Used with permission [107].
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Figure 13a-j. Selected MRI images for Patients 2000 and 7000. Panels a-d show imaging at
the time of neurologic workup when CSF ‘escape’ was initially detected for patients 2000 (a,b)
and 7000 (c,d), demonstrating diffuse T2-prolongation (a,b) and suggesting focal lesions (d) at
the time of CSF ‘escape.’ Panels e-h show follow-up imaging for patient 2000 at 111 days and
patient 7000 at 60 days. Even though neurological symptoms had resolved in both cases,
imaging still shows diffuse leukoencephalopathy (e,f) and hyperintense, diffuse signal alteration of
bilateral white matter (h), despite improvement of previous focal lesions (h). Panels i and j show
imaging for patient 2000 at 567 days follow-up, demonstrating significant interval decrease in T2prolongation. Used with permission [107].
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CSF neopterin was measured in two patients at the time of CSF ‘escape.’ Patient
7066 had a CSF neopterin level of 76.3 nmol/L with a plasma level of 12 nmol/L; patient
5168 had a CSF neopterin of 37.6 nmol/L with a plasma level of 8 nmol/L. Reference
ranges for HIV-uninfected subjects are <5.8 nmol/L in CSF and <8.8 nmol/L in plasma
[173]; for successfully ART-treated HIV-infected subjects, mean 10.8 nmol/L in CSF
[174].
Two patients (1034 and 4065) underwent brain biopsy at the time of CSF
‘escape,’ revealing dense, perivascular lymphocytic infiltrates in the white matter with
extension into the surrounding parenchyma. Immunoperoxidase staining showed a
mixture of mature and immature B- and T-lymphocytes, with CD8+ predominance.

HIV RNA in CSF and Plasma
By definition, all patients had CSF HIV replication at initial evaluation, with a median of
3900 copies/mL (range, 134-9056 copies/mL). All had a plasma HIV RNA <500
copies/mL and 5/10 had a plasma HIV RNA <50 copies/mL at the time CSF ‘escape’ was
discovered. The median plasma viral load was 62 copies/mL (range, <50-380 copies/mL).
For the 5 patients with controlled but detectable plasma HIV RNA (>50 but <500
copies/mL), the CSF HIV RNA was at least 1 log higher than the plasma HIV RNA.
Figure 14 shows longitudinal plasma data for these patients, indicating plasma
control <500 copies/mL in 7/10 patients over the previous 1000 days. Of these, 5/7 had
HIV RNA below the limit of detection (<50 copies/mL) for the previous 1000 days. One
patient had a transient increase in plasma viral load during this period (patient 4065), but
had been well-controlled previously and following this increase. Two had viral loads that
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Figure 14. Longitudinal plasma HIV RNA levels for patients with CSF ‘escape’. HIV RNA is
calculated in days prior to time CSF/plasma discordance was detected (time “0”). Reference
dotted horizontal line indicates log10 500 copies/mL. Corresponding CSF HIV RNA levels are
indicated on the right axis of the graph at the time when CSF escape was identified (“CSF
Escape”) and at a standardized follow-up time point, where repeat CSF was available (“Followup”). Used with permission [107].
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had more recently declined to <500 copies/mL (patients 1034 and 7000). These patients
were included because they presented with new neurologic symptoms in the absence of
alternate pathogens or focal lesions as determined through imaging or brain biopsy, with
CSF ‘escape’ in the setting of preserved immune status and declining plasma HIV RNA.

Viral Resistance and CNS Penetration
Table 7 indicates the results of CNS genotyping and CNS penetration calculations. 6/7
patients on whom resistance gentoyping was conducted in the CSF had NRTI mutations,
5/7 patients had PI mutations, and 2/7 patients had NNRTI mutations. One patient had no
mutations detected on CSF genotyping.
The original antiretroviral regimens for these patients had a median CPE score of
6.5 (range, 3-13). When adjusted for resistance, the median adjusted CPE score was 1
(range, 0-9). Regimens were revised in 9/10 subjects based on CSF findings. The revised
regimens (see Table 7) had a median raw CPE score of 11 (range, 7-16) and median
adjusted CPE score of 4 (range, 4-10).

Changes after Treatment Intervention
Eight out of nine patients demonstrated clinical improvement following neurologic
evaluation and ART regimen optimization. One patient did not improve (patient 5168)
and one patient died from septic shock secondary to presumed bowel ischemia before
treatment was modified (patient 1034).
Follow-up CSF was available in 4/9 patients and demonstrated reduced CSF HIV
RNA levels (from median 5775 copies/mL to median 66 copies/mL) at a median of 70
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Initial Regimen
Site
Patient

Resistance Mutations
Detected in CSF

SF
7066

Not done

MI
9000

NRTI: K65R, K70R, V75I, F77L,
F116Y, Q151M, R211K
NNRTI: none
PI: I54V, A71V, V77I, V82F,
L90M

SF
1034

Not done

SF
7071

NRTI: D67N, T69D, K70R,
L74V, T215F, K219Q
NNRTI: V108I, Y181C, G190A,
F227L
PI: L10I, K20I, M36I, M46I,
I50V, Q58E, L63P, A71V, L90M

SF
4065

NRTI: L74V, M184V, Y115F
NNRTI: Y181C, F227L
PI: L63P, A71T, V77I, I85V

NH
2000

NRTI: M41L, E44D, D67N,
V118I, M184V, L210W, T215Y
NNRTI: none
PI: I13V, K20R, M36I, I54V,
L63P, V82A

GS
5168

Drugs in
Regimen
DDI
SGC
RTV
3TC*
d4T**
LPV/r****
3TC
ZDV
LPV/r
3TC
ZDV****
EFV***
LPV/r****
**
T-20
DDI*
TDF
ATV/r**

New Regimen

Raw
CPE

Adjusted
CPE

3

n/a

Drugs in
Regimen
ABC
NVP
IDV/r

Raw
CPE

Adjusted
CPE

11

n/a

9

8

7

0

TDF*
NVP
APV/r
T-20

9

n/a

Not done

n/a

n/a

2

3TC
TDF
ZDV****
LPV/r****
**
T-20

11

4

1

3TC*
ABC***
ZDV
LPV/r*

12

4

16

4

13

3

3TC*
ABC*
LPV/r****

5

0

3TC*
ABC*
ZDV*
NVP
DRV/r*

NRTI: M41L, V75A, M184I
NNRTI: none
PI: M36I, L63P

3TC*
TDF
ATV/r*

6

1

FTC*
TDF
DRV/r

7

4

MI
8000

Not done

3TC
ABC
FPV/r

8

n/a

3TC
ABC
ZDV
FPV/r

12

n/a

MI
7000

NRTI: none
NNRTI: none
PI: none

FTC
TDF
ATV

9

9

3TC
ZDV
DRV/r

9

9

NH
1000

NRTI: M184I
NNRTI: none
PI: none

FTC*
TDF
ATV/r
RAL

6

FTC*
TDF
ZDV
ATV/r
RAL

13

10

9

Table 7. HIV drug regimens and resistance profiles in patients with CSF/plasma discordance
CPE = central nervous system penetration effectiveness; SF = San Francisco; MI = Milan, Italy; NH =
New Haven; GS = Gothenburg, Sweden; * denotes number of resistance mutations to each drug in
regimen; n/a= not applicable; drug abbreviations: DDI = didanosine, SGC = saquinavir, RTV =
ritonavir, 3TC = lamivudine , d4T = stavudine, LPV = lopinavir, ZDV = zidovudine, EFV = efavirenz, T20 = enfuvirtide, TDF = tenofovir, ATV = atazanavir, ABC = abacavir, FPV = fosamprenavir, FTC =
emtricitabine, RAL = raltegravir, NVP = nevirapine, IDV = indinavir, APV = amprenavir, DRV =
darunavir, /r = boosted with ritonavir. Used with permission [107].
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days following change in drug regimen (range, 11-189 days). In 3/4 cases, discordance
between CSF and plasma resolved at this follow-up point; in 1 case, discordance
persisted at a lower level (patient 5168 with 340 copies/mL in the CSF); this patient’s
abnormalities did not improve after 189 days on the new regimen.
Figure 13e-h shows short-term follow-up imaging for patients 2000 and 7000. At
60 days, MRI for patient 7000 showed resolution of most focal lesions, but the
development of a diffuse leukoencephalopathy despite resolution of symptoms. Similarly,
patient 2000 had persistent diffuse white matter hyperintensities on MRI at 111 days,
with subsequent significant decrease at 346 and 567 days follow-up.

Discussion
We report 10 cases of elevated CSF HIV RNA in the setting of plasma suppression in
patients with well-controlled HIV infection, with long-term plasma control and CD4+ T
cell counts indicating preserved immune status at the time when neurologic symptoms
developed. These cases demonstrate an unusual but clinically important phenomenon of
CSF ‘escape’ associated with incident neurologic signs and symptoms in patients with
chronic treated HIV infection.

Patient Characteristics and Clinical Presentation
The patients we report comprise a representative sample of those living with ART-treated
HIV. This includes individuals with persistently suppressed plasma HIV RNA over many
years (patient 2000), those who have been under control for a number of years (patients
1000, 7066, 7071, 9000, and 5168), those with a recent ‘blip’ (patient 4065), and those
with an unclear history who are coming under control (patients 1034 and 7000). The

76

common clinical picture of neurologic abnormalities across this spectrum of patients
suggests that CSF ‘escape’ is a relevant consideration in a variety of clinical contexts.
Patients experienced a variety of neurologic symptoms including cognitive,
sensory, and motor impairment. Onset was most often subacute, impairment varied in
severity, and abnormalities progressed over time. Overall, the neurologic symptoms
reflect a level of debilitation that was significant and involved a range of functional
domains. They reported a loss of function consistent with the significant impact that
neurological symptoms are known to have on quality of life [32].

Immune Status
Despite relatively reconstituted immune status at the time of evaluation, all patients had
CD4+ T cell nadirs <250 cells/mm3, with many below 100 cells/mm3, consistent with a
previous report of a median nadir CD4+ count of 55 cells/mm3 in similar patients [18]. A
history of advanced immunosuppression may confer increased risk for prior local CNS
infection and compartmentalization [175], which, despite peripheral CD4+ improvement,
fails to be entirely suppressed by ART. Clinically, the CD4+ nadir might be an important
consideration in the assessment of patients with new neurological abnormalities.

Imaging Results
MRI findings were consistent among patients and with those reported in previous cases
[18,167,169]. Furthermore, they are similar but not identical to those classically
identified in typical HIV-associated dementia in patients off of ART. White matter
hyperintensities on T2-weighted and FLAIR imaging suggest a generalized inflammatory
process consistent with diffuse encephalitis, and similar to findings reported in patients
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failing antiretroviral therapy [176]. Comparison of MRI results at the time of presentation
(Figure 13a-d) and short and long-term follow-up (Figure 13e-h, 13i-j, respectively)
suggests that this process is associated with findings on imaging that may persist after the
resolution of symptoms, and may take months to years to resolve completely. Still, the
nature of these imaging findings remains incompletely understood.

Antiretroviral Regimens and Patient Adherence
One concern with previously reported cases of CSF ‘escape’ has been that some patients
have been on atypical, incomplete, outdated, or “last-resort” salvage regimens [18]. All
patients in our study were on appropriate multi-drug combination ART regimens before
they developed symptoms, although some older regimens may be outdated by current
standards. No patients in our study were on mono- or dual-therapy.
Preserved immune status and suppression of plasma viremia suggest adherence
with ART, though the contribution of suboptimal adherence cannot be ruled out.
Theoretically, partially reduced adherence may lead to insufficient drug concentrations in
the CSF while maintaining satisfactory concentrations in plasma. CSF drug levels may
therefore be an important consideration in this subset of patients, as has been suggested
elsewhere [18]. CSF ‘escape’ may arise secondary to differences in susceptibility
between HIV subpopulations in blood and CSF [177-180] due to the selection of resistant
virus in the context of sub-therapeutic drug levels in the CNS compartment [181].

CNS Drug Penetration and Viral Resistance
While it has been argued that CNS drug penetration may be an important factor in the
pathogenesis of CSF ‘escape’ [104], these cases indicate that viral resistance should also
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be considered. Resistance to at least one drug in the regimen was common. The
“adjusted” CPE score represents a first attempt to incorporate resistance into a numerical
calculation of drug effectiveness, and conservatively assumes that a single mutation will
confer complete resistance to a drug, though, in fact, the drugs may remain partially
effective despite the mutations. While it is unclear to what extent clinical improvement
resulted from treatment interventions in the cases included here, most patients improved
when their regimens were adjusted with regard to both penetration and resistance. This
suggests that regimen modifications should be based on more than penetration alone.

CNS Inflammation
Taken together, the range and quality of neurological dysfunction and the MRI findings
in these patients have substantial overlap with typical findings in HIV-associated
dementia. However, despite this overlap, these are not identical to those in HAD and we
believe that the etiology of these findings is different than that of HAD in the absence of
treatment. In accordance with previous reports [18,167,169], markedly elevated CSF total
protein levels and WBC counts in our subjects compared to healthy HIV-uninfected
controls and neuro-asymptomatic HIV-infected subjects on “successful” ART [30]
indicate that a CNS inflammatory response is occurring in these patients. The pronounced
inflammation and CD8+ T cell infiltration noted on brain biopsy suggests that CSF
‘escape’ in the setting of an immune system reconstituted by systemically successful
ART is associated with a degree of local inflammation distinct from typical HAD or HIV
encephalitis. CSF neopterin, which is elevated in HAD and reduced by ART
[174,182,183], was markedly increased in comparison to plasma neopterin and typical
values of CSF neopterin in HIV-infected, ART-suppressed subjects. This provides
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evidence that in CSF ‘escape,’ inflammation may be relatively compartmentalized in the
CNS. The role of inflammation in this disorder may determine the distinct neurotropism
for these lesions, as reflected in MRI and clinical symptoms.
Given the observation that symptomatic CSF ‘escape’ is accompanied by CNS
inflammation, a moderately reconstituted immune system may play an important role in
both eliciting a symptomatic inflammatory response and in providing a substrate for
ongoing discordant HIV replication within the CNS. Since all of the subjects had
preserved immune function and none had recently initiated ART, typical immune
reconstitution inflammatory syndrome (IRIS) was not considered the primary cause of
these abnormalities. Nevertheless, the combination of persistent CNS infection and
relatively preserved immune response, including an HIV-specific response, may generate
immunopathology in cases of CSF ‘escape.’ This is analogous to IRIS [184], but may
differ in that it represents not the effects of immune reconstitution, but rather a “stable
state” of antigen and immune response within the CNS.

Limitations
This analysis is limited by its retrospective approach, which utilized chart reviews and
was constrained to studies previously performed during clinical evaluation and research
protocols. It is unclear what the prevalence of CSF ‘escape’ may be in the general HIVinfected population, as patients with minor neurologic complaints are relatively unlikely
to undergo detailed CNS evaluations. Our follow-up data are limited in many cases
because further studies were not pursued once symptoms resolved.
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IMPLICATIONS OF THE THESIS RESEARCH
Each of these projects adds to what is known regarding neurological manifestations of
HIV in the era of combined antriretroviral therapy and contribute to the understanding of
HAND. The first study answers important questions about the implications of the very
first stages of HIV infection in the central nervous system and reveals that neuronal
injury occurs earlier than previously thought. This provides a foundation for the
development of further evidence that injury occurring before antiretroviral therapy is
initiated contributes to the etiology of HAND. The second study contributes to the
understanding of the activity of HIV within the central nervous system compartment and
shows how its very presence can have a profound clinical significance for individuals
who are otherwise living with HIV as a chronic disease. A better understanding of the
phenomenon of CSF ‘escape’ will help clinicians to more specifically tailor therapy
toward the CNS and will help scientists to understand how the independent evolution of
virus within the CNS could contribute to the development of HAND.

Implications for Primary HIV Infection
Our finding of neuronal injury during primary HIV infection has important implications
for the understanding of HIV pathogenesis and management. Previously, neuronal injury
was thought to be a product of prolonged infection. The presence of elevated CSF NFL
compared to the upper limit of normal for age in 44% of our subjects adds to a growing
body of evidence suggesting that neurological injury is present beginning in primary HIV
infection.
It is particularly notable that the elevations in neurofilament light chain and
amyloid-beta 42 appear to occur through different pathways, with the former correlating
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with multiple CSF and metabolic markers of neuroinflammation and the latter related to
some other process, such as disruption of the blood-brain barrier or decreased breakdown
secondary to viral inhibition. This suggests that we may need to invoke more than just
infection or inflammation alone in characterizing the CNS perturbations present during
primary HIV infection.
It has long been known that primary HIV infection may be complicated by central
and peripheral nervous system involvement. In this study, evidence of neuronal injury
was found in patients even without clinical evidence of neurological symptoms.
Furthermore, evidence of neuronal injury did not correlate with clinical signs of
abnormalities in neuropsychological testing. Further study is required to determine
whether this injury is sub-clinical, if the lack of correlation is due to the relative
insensitivity of this type of testing, whether the injury resolves with or without treatment,
and if it has long-term neurological implications.
Although treatment with cART is able to suppress viral levels in both the plasma
and CSF, a proportion of patients have ongoing brain atrophy and neurological
impairment for unclear reasons [185]. One possible explanation for this phenomenon is
that neurological injury begins accruing early in the disease course, including during
primary HIV infection. Thus, while initiation of cART typically occurs once an
immunological threshold is crossed after several years of infection, CNS injury might
begin soon after seroconversion, in the setting of early neuroinvasion and immune
activation. If this were the case, it would provide additional evidence for early
pharmacological intervention in HIV infection aimed at mitigating CNS injury.
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Implications for Central Nervous System Compartmentalization
Our description of CSF ‘escape’ in the patients we describe here contributes to the
literature on this rare but clinically significant process. It is crucial that all physicians
who care for patients with HIV, not just neurologists, be aware of this unusual
manifestation of HIV disease. These cases reflect that new neurological symptoms in the
context of standard cART regimens and well-controlled plasma HIV infection should not
be dismissed and instead warrant an evaluation of the CSF to determine whether viral
replication is occurring and, if so, whether the virus in the CSF compartment possesses
resistance to the regimen being used to control the virus in the plasma compartment.
While the investigation of CSF HIV is standard practice in the guidelines for HIV
management in many European countries, this is not the case in the United States. CSF
HIV viral load and genotyping are difficult tests to order at many U.S. medical centers,
and are generally not a standard offering by most hospital laboratories. This descriptive
analysis of 10 cases of CSF HIV ‘escape’ demonstrates that CSF HIV analysis can be an
important diagnostic tool and should be available to clinicians for the purpose of
measuring HIV RNA concentration and identifying resistance, especially in patients who
develop new neurological symptoms that cannot otherwise be explained. These cases
underscore the need for further investigation into the mechanism and consequences of
HIV replication and persistence in the CNS.

General Implications for HIV-Associated Neurocognitive Disorder
Both of these studies reflect what is becoming an increasingly accepted fact about the
pathogenic mechanisms of HIV infection – that the body’s reaction to HIV can be as
damaging as the activity of the virus itself. Although the two processes described here,
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primary HIV infection and CSF HIV ‘escape,’ take place at distinct time points in the
course of the disease, both appear to be associated with, and possibly caused by,
mechanisms of immune activation and inflammation within the central nervous system.
The inflammatory milieu that is induced by the activity of HIV in invading cells and
triggering an immune response has important implications throughout the time course of
infection, and may be particularly important for our understanding of HAND.
In the earliest stages of primary infection, the virus crosses the blood-brain barrier
for the first time and initiates a cascade of cytokines that contribute to breakdown of that
barrier, as well as CSF pleocytosis, macrophage and lymphocyte activation, interference
with neuronal synthesis and maintenance pathways, and ultimately neuronal injury that
can be detected by biomarker and neuroimaging perturbations. Whether these patients
become symptomatic at the time of these perturbations or later in the disease course
remains to be seen. And while control of the virus through the initiation of antiretroviral
therapy can decrease the viral load and quiet the immune response, the CNS compartment
remains particularly vulnerable to further insult. In some patients, this means the
development of some degree of mild HAND, or worse, HIV-associated dementia late in
the course of unsuccessfully or sub-optimally treated infection. In others, the initiation of
therapy might lead to a profound immune reconstitution that precipitates the perivascular
inflammation and leukoencephaloathy consistent with IRIS [186-188]. And in others still,
minimal non-adherence, reduced drug activity, or some yet-unknown factor may result in
the development of a low-level CSF viral proliferation in the setting of suppressed or
well-controlled plasma virus. This can initiate an immune cascade that, although meant to
respond to the replicating virus, may ultimately end up feeding its proliferation by
providing a substrate to infect.
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FUTURE DIRECTIONS
While we have identified cross-sectional changes in biomarkers indicating neuronal
damage during primary HIV infection, it would be useful to characterize the onset of
abnormal CSF neurofilament light chain and its longitudinal changes over the time course
of primary infection and early HIV disease. We have access to a cohort of HIV-infected
individuals from Thailand from whom we have collected CSF at the time of
seroconversion. Analysis of these samples will provide insight into the timing of neuronal
injury and help to determine whether this is present before the median 3.1 month time
point in the current study. It will also be instructive to study subjects with neuroasymptomatic advanced (CD4 <200) and non-advanced (CD4 >200) chronic HIV
infection to determine whether the latter group continues to show evidence of neuronal
damage later in the course of infection. These studies will fill an important gap in the
understanding of the pathophysiological consequences of HIV infection between primary
HIV infection and late-stage AIDS. Whether biomarker abnormalities during primary
infection predict later HAND and HAD is unknown. The subjects in the primary infection
study were all antiretroviral naïve at baseline, but many began treatment at subsequent
visits. The analysis of longitudinal trends in NFL in untreated subjects and the
comparison of NFL trends during periods with and without therapy in subjects who
initiate cART will indicate whether neurological damage continues throughout the course
of infection and whether initiation of therapy can attenuate this damage. Data using
proton-MRS metabolites suggest that worsening neuronal injury may be mitigated by the
initiation of therapy [129].
With regard to CSF ‘escape,’ a greater understanding of this condition will come
from the publication of more detailed cases of the disease process and its clinical
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manifestations. In addition, more in-depth neuroimaging and tissue analysis will help to
distinguish the pathophysiological mechanisms of this condition from those seen in IRIS.
Finally, a better assessment of medication adherence in these patients will help to
determine whether this is a determining factor in the pathogenesis of the disease, as will
further research into issues related to HIV compartmentalization in the CNS.
Progress in both of these areas of research will help to better describe and
understand the pathophysiological mechanisms responsible for HAND.

CONCLUSIONS
Thirty years after the identification of the very first cases of HIV and AIDS, the scientific
community has made great strides toward understanding the pathogenesis, clinical
manifestations, and public health implications of the disease. But three decades of
scientific research have generated as many questions as they have answered, and millions
of individuals are still acquiring the virus each year. The central nervous system is
becoming increasingly recognized as a crucial frontier in the battle against HIV disease,
both because of the dramatic neurological sequelae of HIV infection and the difficulty in
accessing and controlling the virus within this compartment. The content of this thesis
makes a modest contribution to the growing understanding of the impact of both acute
and chronic HIV infection on the central nervous system, and underscores that a great
deal of work is yet to be done in this area of investigation. As HIV/AIDS continues its
shift toward becoming a chronically managed disease, it is the responsibility of
physicians and scientists to more fully understand how infection with this virus affects a
patient from the moment of transmission, through years of chronic infection, until the
moment of death or, hopefully within this generation, cure.
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Infections of the Nervous System” in the Fifth Edition of Aminoff’s Neurology and
General Medicine, to be published in 2013.
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APPENDICES

Plasma/CSF Viral Discordance Case Series
Patient Information Checklist
Cases: Generally well-controlled HIV+ patients on HAART presenting with
neurological symptoms in the setting of previous viral suppression who are
determined to have detectable CSF viral load on lumbar puncture.

General Information
 Year of HIV diagnosis
 Nadir CD4 (if known)
 Known co-infections or opportunistic infections
 Note containing H&P for neurological symptoms
 HIV regimen at time of visit for neurological symptoms
 # of months on this regimen
 list of previous HIV regimens, with dates (if available)
 # of months of VL suppression (either < detection threshold or undetectable)
 Complete longitudinal information on plasma VL and CD4 count from diagnosis
until present (usually available as a flowsheet in medical records)
Lumbar Puncture Information
 Date of LP
 Plasma CD4 at time of LP
 Plasma VL at time of LP
 CSF chemistries and cytology (including protein, glucose, RBC, WBC, nucleated
cells, %lymphs, %monos)
 CSF VL
 CSF HIV genotype (if done)
Additional Information
 Brain imaging results
 EEG results
 New HIV regimen
 Follow-up note indicating improvement

Primary HIV-1 infection is characterized by elevation of
cerebrospinal fluid biomarkers indicating early neuronal damage
Michael Peluso1, Richard W. Price2, Julia Peterson2, Evelyn Lee2, Dietmar Fuchs3, Bruce Brew4, Paola Cinque5, Lars Hagberg6, Henrik Zetterberg6, Magnus Gisslén6, Serena Spudich1
1Yale

University School of Medicine, New Haven, USA; 2University of California – San Francisco, San Francisco, USA; 3Innsbruck Medical University, Innsbruck, Austria; 4St. Vincent’s Hospital, Sydney, Australia; 5San Raffaele Scientific Institute, Milan, Italy; 6Gothenburg University, Gothenburg, Sweden

Background
• Neurologic impairment is detected in up to 50% of patients
with HIV, even in the setting of antiretroviral therapy1
• Cerebrospinal fluid (CSF) biomarkers of neuronal injury, such as
neurofilament light chain (NFL), are elevated in subjects with
advanced HIV-infection and HIV-associated dementia2
• We hypothesized that evidence of neuronal injury might be
detected in subjects recruited during primary HIV infection (PHI),
within the first year after HIV transmission

Methods
• In antiretroviral naïve subjects with PHI, CSF NFL was analyzed
using a new, highly-sensitive, two-site enzymatic quantitative
immunoassay with a lower limit of detection of 50 ng/L
• Detection of t-tau, β-amyloid, and soluble amyloid precursor
protein-alpha and -beta (sAPP-α; sAPP-β) used standard ELISAs
• To investigate mechanisms, we examined levels of biomarkers
with respect to other laboratory parameters of CNS HIV infection
• Analyses employed Mann-Whitney test, Spearman correlations
NFL
T-tau
β-Amyloid
sAPP-α,β
Neopterin
IP-10
MCP-1

Structural component of myelinated axons
Associated with microtubules in cortical axons
Abnormal amyloid protein in Alzheimer’s disease
Amyloid synthesis and processing
Marker of macrophage activation
Cytokine recruiting lymphocytes
Cytokine recruiting monocytes

Variable

Spearman r

p-value

Log Plasma VL

0.23

0.040

Log CSF VL

0.23

0.040

Days of Infection

-0.01

0.903

NPZ-4

0.18

0.154

CSF WBC

0.33

0.003

CSF Protein

0.61

<0.0001

p-value

CSF:plasma albumin

0.59

<0.0001

0.03
0.002
< 0.001
< 0.001
0.416
< 0.001

T-tau

0.51

0.004

P-tau

0.42

0.058

Amyloid-β 42

0.51

0.018

sAPP-a

0.28

0.232

sAPP-β

0.07

0.758

Blood Neopterin

0.23

0.053

CSF Neopterin

0.40

0.002

IP-10

0.42

0.001

MCP-1

0.16

0.235

Results
PHI
HIVn=84
n = 25
% Male
95.2%
80%
Age
36 (18-61)
43 (26-66)
Days Infected 96.5 (15-376)
CD4 Count 546 (111-1608) 836 (488-1627)
CD8 Count 985 (161-9063) 550 (157-1031)
Log Plasma VL 4.6 (1.7-7.1)
Log CSF VL
2.9 (1.3-6.1)
CSF Protein
41 (21-343)
47 (21-65)
CSF WBC
6 (0-86)
1 (0-6)
% Neuro Sx

10.7%

-

Figure 1. CSF biomarker comparisons between PHI subjects and
HIV-uninfected controls. Lines represent median; range. HIV- =
HIV uninfected; PHI = primary HIV infection; NFL = neurofilament
light chain; sAPP = soluble amyloid precursor protein.

-

Table 1. Descriptive and demographic characteristics of PHI
subjects and HIV-uninfected controls. Data reported as
percentages or median (range). VL= viral load.

Table 2. Correlates of NFL in PHI subjects. VL = viral load; NPZ-4
= composite neuropsychologic Z-score; WBC = white blood cells;
sAPP = soluble amyloid precursor protein.

Figure 2. Correlates of NFL in PHI subjects. Bold line indicates
linear approximation of relationship; dotted lines represent 95%
confidence intervals.

Conclusions
• Biomarkers of neuronal damage are elevated in subjects with
PHI compared to HIV-uninfected controls
• NFL, a sensitive marker of neuronal injury, correlates with
markers of CSF inflammation during PHI
• These findings suggest that HIV-related neuronal damage starts
during early HIV-infection and is mediated by neuroimmune
activation during this period
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Discordance between Plasma and Cerebrospinal Fluid HIV in Virologically Controlled
Patients Presenting with Neurologic Symptoms
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Table 2. Neurologic studies in patients with CSF ‘escape’

Introduction

Table 3. Drug regimens and resistance profiles in patients with CSF ‘escape’

Cerebrospinal Fluid Analysis

 Elevated HIV RNA levels in the cerebrospinal fluid (CSF) can be associated with
HIV encephalitis (HIVE) and HIV-associated dementia (HAD)
 Antiretroviral therapy (ART) suppresses plasma and CSF HIV RNA and improves
neurologic outcomes in patients with HIV
 A subset of patients may develop neurologic symptoms in the setting of long-term
plasma viral control1

Methods
Study Design Retrospective case series of virologically controlled HIV-infected
patients on ART with incident neurologic abnormalities, determined to have CSF
„escape,‟ defined as detectable CSF HIV RNA in the setting of suppressed plasma
levels or CSF HIV RNA >1 log higher than plasma RNA1

Site,
ID
SF
7066
MI
9000
SF
1034
SF
7071

Plasma HIV
RNA
(copies/mL)

HIV RNA
(copies/mL)

Protein
(mg/dL)

WBC
(cells/mm3)

380

9056

162

50

MRI Findings
Not done

372

8000

170

0

Diffuse white matter abnormalities

<50

378

89

6

Patchy periventricular white matter abnormalities

<50

8320

60

33

Not done

SF
4065

184

4570

74

14

NH
2000

<50

613

77

28

GS
5168

118

3230

n/a

9

MI
8000

<50

134

121

15

Measurements Clinical signs and symptoms, historical virologic parameters,
magnetic resonance imaging (MRI), CSF parameters, viral resistance and drug
penetration in the CNS, and treatment intervention

MI
7000

98

5200

137

200

NH
1000

<50

460

46

11

Results

WBC = white blood cells; n/a = not available

Patchy subcortical/ periventricular white matter
abnormalities with involvement of corpus collosum and
cerebellum
Symmetric subcortical/ periventricular white matter
abnormalities extending into cerebellum
Slight deformity of frontal ventricular horns, stable
compared to previous examinations. Otherwise
normal.

Periventricular/lenticular/posterior internal capsule/
cingular cortex white matter abnormalities extending
into cerebellum; diffuse pial contrast enhancement
Cortical/subcortical/periventricular white matter
abnormalities

Site,
ID
SF
7066
MI
9000
SF
1034

SF
7071

SF
4065

NH
2000
GS
5168

Time of Presentation

Stable
plasma HIV†
(copies/mL:
months)

CD4+
T cell
count
(cells/mm3)

Plasma
HIV RNA
(copies/mL)

318

380

Age/
Sex
(years)

Nadir CD4+
T cell count
(cells/mm3)

45/M

55

<50: n/a
<500: 23

15

<50: 28
<500: 28

46/F

51/M

49/M

49/M

55/M

45/F

80

8

<50: 2
<500: 2

<50: 30
<500: 30

4

<50: 2
<500: 7

60

<50: 96
<500: 96

55

<50: 47
<500: 60

305

588

444

520

308

660

372

<50

<50

Drug
regimen
DDI
SGC
RTV
3TC
d4T
LPV/r
3TC
ZDV
LPV/r
3TC
ZDV
EFV
LPV/r
T-20

184

DDI
TDF
ATV/r

<50

3TC
ABC
LPV/r

118

3TC
TDF
ATV/r

Neurologic
signs/symptoms
Cognitive impairment
Gait ataxia
Coma
Tremor
Vertigo
Cognitive impairment
Gait ataxia
Tremor

Diplopia
Dysarthria
Dysphagia
Gait ataxia
Aphasia
Gait ataxia
Sensory impairment
Tremor

Cognitive impairment
MI
<50: 27
Dysarthria
45/M
222
545
<50
8000
<500: 27
Sensory impairment
Vertigo
Diplopia
FTC
MI
<50: 4
Dysarthria
26/M
9
290
98
TDF
7000
<500: 12
Gait ataxia
ATV
Tremor
Aphasia
FTC
Cognitive impairment
NH
<50: 12
TDF
49/M
180
627
<50
Gait ataxia
1000
<500: 43
ATV/r
Tremor
RAL
Vertigo
SF = San Francisco; MI = Milan, Italy; NH = New Haven; GS = Gothenburg, Sweden; n/a = not applicable; † = length
of time <500 copies/mL includes times when patient was <50 copies/mL
3TC
ABC
FPV/r

Raw
CPE

Resistance Mutations
Detected in CSF

SF
7066

DDI
SGC
RTV

3

Not done

MI
9000

3TC*
d4T**
LPV/r****

7

NRTI: K65R, K70R, V75I, F77L,
F116Y, Q151M, R211K
NNRTI: none
PI: I54V, A71V, V77I, V82F, L90M

SF
1034

3TC
ZDV
LPV/r

9

Not done

SF
7071

3TC
ZDV****
EFV***
LPV/r******
T-20

13

NRTI: D67N, T69D, K70R, L74V,
T215F, K219Q
NNRTI: V108I, Y181C, G190A,
F227L
PI: L10I, K20I, M36I, M46I, I50V,
Q58E, L63P, A71V, L90M

SF
4065

DDI*
TDF
ATV/r**

3

NRTI: L74V, M184V, Y115F
NNRTI: Y181C, F227L
PI: L63P, A71T, V77I, I85V

Initial Regimen
Adjusted CPE

New
Regimen

New Regimen
Adjusted CPE

n/a

ABC
NVP
IDV/r

11†

0

TDF*
NVP
APV/r
T-20

8

n/a

Not done

n/a

2

3TC
TDF
ZDV****
LPV/r******
T-20

4

NRTI: M41L, E44D, D67N, V118I,
M184V, L210W, T215Y
NNRTI: none
PI: I13V, K20R, M36I, I54V, L63P,
V82A
NRTI: M41L, V75A, M184I
NNRTI: none
PI: M36I, L63P

1

NH
2000

3TC*
ABC*
LPV/r****

5

GS
5168

3TC*
TDF
ATV/r*

6

MI
8000

3TC
ABC
FPV/r

8

Not done

MI
7000

FTC
TDF
ATV

9

NRTI: none
NNRTI: none
PI: none

9

NH
1000

FTC*
TDF
ATV/r
RAL

9

NRTI: M184I
NNRTI: none
PI: none

6

0

1

n/a

3TC*
ABC***
ZDV
LPV/r*
3TC*
ABC*
ZDV*
NVP
DRV/r*
FTC*
TDF
DRV/r
3TC
ABC
ZDV
FPV/r
3TC
ZDV
DRV/r
FTC*
TDF
ZDV
ATV/r
RAL

Summary of Key Findings:
Virologic History and Time of Presentation
Data reported as medians
• Duration HIV Infection
• Time < 500 copies/mL
• Time < 50 copies/mL
• Duration on Regimen

16.2 years
27.5 months
19.5 months
21 months

• CSF HIV
• Plasma HIV
• CD4+ T cells
• CD4+ Nadir

3900 copies/mL
62 copies/mL
482 cells/uL
35 cells/uL

g

66 Day Follow-up
h

567 Day Follow-up
4

i

j

4

11†

9

10

Additional Findings

Figure 1. Longitudinal plasma HIV RNA levels prior to CSF ‘escape.’ HIV RNA
calculated in days prior to CSF „escape‟ (time “0”). Corresponding CSF HIV RNA levels
are indicated on the right axis of the graph (“CSF Escape”).

e

111 Day Follow-up
f

c

Patient 7000 Baseline CSF ‘Escape’
d

4

Raw CPE = central nervous system penetration effectiveness score2; “adjusted” CPE calculated by assigning drugs
with known resistance mutation as “0” and re-calculating CPE; * denotes number of resistance mutations to each drug
in regimen according to International Antiviral Society-USA Guidelines; n/a= not available; † = raw score, adjusted
score not available because genotyping not done

Cognitive impairment
Gait ataxia
Sensory impairment

Cognitive impairment

Initial
Regimen

Diffuse white matter abnormalities

Table 1. Demographics and HIV history of patients with CSF ‘escape’
Historical Data

Site,
ID

a

Patient 2000 Baseline CSF ‘Escape’
b

• Plasma neopterin normal or slightly elevated in 2 patients
• 12 nmol/L, 8 nmol/L (reference 8.8 nmol/L in HIV-uninfected subjects)
• CSF neopterin elevated in 2 patients
• 76.3 nmol/L, 37.6 nmol/L (reference 10.8 nmol/L in ART-treated subjects)
• Brain biopsies in 2 patients
• dense, perivascular lymphocytic infiltrates in white matter with extension into
surrounding parenchyma.
• mixture of mature and immature B- and T-lymphocytes, CD8+ predominance
Changes after Treatment Intervention
• 8/9 patients demonstrated clinical improvement
• Follow-up CSF available in 4 patients; 3/4 had discordance resolve
• Median pre-intervention CSF HIV 5775 copies/mL at time of CSF “escape”
• Median post- intervention CSF HIV 66 copies/mL at median 70 days on new
regimen

Figure 2a-j. MRI images. Initial MRI shows diffuse T2-prolongation (a,b) and focal
lesions (c,d). Follow-up shows diffuse leukoencephalopathy despite symptom
resolution (e-h) in the short-term and significant improvement at 567 days (i,j).

Summary & Conclusions
 New neurologic symptoms in the context of well-controlled plasma HIV warrant
an evaluation of the CSF to determine whether viral replication is occurring
 CSF HIV analysis can be an important diagnostic tool and should be available to
clinicians for the purpose of measuring HIV RNA and identifying resistance
 A moderately reconstituted immune system may play an important role in both
eliciting a symptomatic inflammatory response and in providing a substrate for
ongoing discordant HIV replication within the CNS
 Further investigation is needed into the mechanism and consequences of HIV
replication and persistence in the CNS
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